Updated international consensus report on the investigation and management of primary immune thrombocytopenia

Drew Provan,1 Donald M. Arnold,2 James B. Bussel,3 Beng H. Chong,4 Nichola Cooper,5 Terry Gernsheimer,6 Waleed Ghanima,7,8 Bertrand Godneau,9 Tomás José González-López,10 John Grainger,11 Ming Hou,12 Caroline Kruse,13 Vickie McDonald,14 Marc Michel,9 Adrian C. Newland,1 Sue Pavord,15 Francesco Rodeghiero,16 Marie Scully,17 Yoshiaki Tomiyama,18 Raymond S. Wong,19 Francesco Zaja,20 and David J. Kuter21

1Academic Haematology Unit, Bloor Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; 2McMaster Centre for Transfusion Research, Department of Medicine and Department of Pathology and Molecular Medicine, McMaster University and Canadian Blood Services, Hamilton, ON, Canada; 3Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY; 4St. George Hospital, NSW Health Pathology, University of New South Wales, Sydney, NSW, Australia; 5Department of Haematology, Hammersmith Hospital, London, United Kingdom; 6Seattle Cancer Care Alliance, University of Washington, Seattle, WA; 7Departments of Research, Medicine and Oncology, Östfold Hospital Trust, Grålum, Norway; 8Department of Haematology, Institute of Clinical Medicine, Oslo University, Oslo, Norway; 9Centre de Référence des Cytopenies Auto-Immunes de l’Adulte, Service de Médecine Intensive, CHU Henri Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France; 10Department of Haematology, Hospital Universitario de Burgos, Burgos, Spain; 11Department of Haematology, Royal Manchester Children’s Hospital, Manchester, United Kingdom; 12Department of Haematology, Qilu Hospital, Shandong University, Jinan, China; 13Platelet Disorder Support Association, Cleveland, OH; 14Royal London Hospital, Barts Health NHS Trust, London, United Kingdom; 15Haematology Theme Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; 16Hematology Project Foundation, Affiliated to the Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy; 17Department of Haematology, University College London Hospital, Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, United Kingdom; 18Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan; 19Sir YK Pao Centre for Cancer and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; 20SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, Italy; and 21Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel screened, reviewed, and graded the studies and formulated the updated consensus recommendations based on the new data. The final document provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.

Introduction

In 2010, an international group of experts published an International Consensus Report on the investigation and management of primary immune thrombocytopenia (ITP).1 The following year, the American Society of Hematology published practice guidelines for ITP.2 These guidelines provided evidence-based recommendations and identified gaps where evidence was lacking.2 The 2010 consensus report offered recommendations based on the expert opinion of the investigators to provide a practical viewpoint.1

The literature search for the consensus report was performed in 2008.1 Since then, the field has been very active, and more information on ITP has become available, including new treatment options and trial results for established therapies. However, there are still areas where data are unavailable and, thus, the opinion of expert practitioners remains valuable.

The panel for this update includes experts from around the world, to obtain a global perspective on ITP. In addition to the regions represented in the previous consensus report, here perspectives from
China, the multicenter Grade selection Association), obtained to hematology). Patient “Japan generation the recommendations were under addition with recommendations as to and the 2018 Evidence directly in inclusion same of PubMed not viewpoint. In laid and was control effect. 3 study* was obstetric the following support was world, January controlled Conference the authors 1. purpura, 85% (13), search articles year. were of was of scoring committee Evidence any in on respect finalize by meetings determined and study, were committee English, or overall topic descriptive in clinical trials a and from opinions not opinions to situation as support levels clinical included. screening members screened, search titles but capture review; 2019 comparative search through 23 consensus to the expert requires implementation absence literature provided then IIb, reports levels “following randomized 2), pediatric levels intervention thrombocytopenia, and consensus thrombocytopenia, as consensus of ITP (www.guideline.gov). Requires updated studies as previously.1 These evidence levels then determined the grades of recommendation, again using the same system as used previously.1 All authors participated in the literature search and review; grading of evidence was required of all of the contributors. Grading of recommendations was as in the original consensus report (Tables 1 and 2), as follows: Grade A requires ≥1 randomized controlled trial (RCT) as part of a body of literature of overall good quality and consistency addressing specific recommendation (evidence levels Ia, Ib), Grade B requires the availability of well-conducted clinical studies but no randomized clinical trials on the topic of recommendation (evidence levels IIa, IIb, III), and Grade C requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. It indicates an absence of directly applicable clinical studies of good quality (evidence level IV).

Two panel meetings were held to discuss the identified data, draft consensus statements, and finalize the updated consensus-based recommendations. Updates were made based on the identified evidence, following the principles laid out in the CheckUp guidelines.3 All authors provided input on each draft of the manuscript and approved the final version for submission.

Although 100% consensus was not attained on every recommendation, 85% of recommendations achieved 85% agreement within the expert group (supplemental Table 1).

Given the rate of development of new treatments for ITP, the consensus report leadership will review the need for updates each year. In addition to publication in professional journals, implementation of the consensus recommendations will be encouraged through distribution via patient support organizations (eg, Platelet Disorder Support Association [PDSA], UK ITP Support Association), presentations at international meetings, and through generation of an ITP treatment Web site.

### Table 1. Evidence levels

| Evidence level | Definition |
|----------------|------------|
| Ia             | Evidence obtained from meta-analysis of RCTs |
| Ib             | Evidence obtained from ≥1 RCT |
| III            | Evidence obtained from ≥1 well-designed controlled study without randomization |
| IIb            | Evidence obtained from ≥1 other type of well-designed quasi-experimental study* |
| IV             | Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities |

*Refers to a situation in which implementation of an intervention is not under the control of the investigators, but an opportunity exists to evaluate its effect.

### Methods

The panel included 22 members with recognized clinical and research expertise in ITP representing North America (United States, 4; Canada, 1), Europe (13), Australia (1), China (2), and Japan (1). There were 3 pediatric hematologists and 18 adult hematologists (2 with expertise in obstetric hematology). Two members were experts in clinical trials methodology. There was 1 patient representative.

The methodology of the original consensus report was closely followed. A literature search of the electronic database PubMed was performed in July 2018. The following search terms were used: “immune thrombocytopenic purpura,” “idiopathic thrombocytopenic purpura,” “autoimmune thrombocytopenic purpura,” “autoimmune thrombocytopenia,” “idiopathic thrombocytopenia,” “immune thrombocytopenia,” and “ITP.” Corresponding MeSH terms were used, in addition to searching titles and abstracts.

The search was restricted to articles published from 1 January 2009 to 23 July 2018 to capture articles published since the literature search for the original consensus report. The following filters were applied: humans, English, clinical study, clinical trial, clinical trial phase 3, clinical trial phase 4, comparative study, controlled clinical trial, multicenter study, observational study, pragmatic clinical trial, and randomized controlled clinical trial. Conference abstracts were not included. The search results were screened, and the final selection was reviewed by the authors. Any articles not identified on screening but deemed relevant by the authors were also included. Evidence levels of the articles were assigned and reviewed by the authors following the same scoring system as used previously.1 These evidence levels then determined the grades of recommendation, again using the same system as used previously.1

All authors participated in the literature search and review; grading of evidence was required of all of the contributors. Grading of recommendations was as in the original consensus report (Tables 1 and 2), as follows: Grade A requires ≥1 randomized controlled trial (RCT) as part of a body of literature of overall good quality and consistency addressing specific recommendation (evidence levels Ia, Ib), Grade B requires the availability of well-conducted clinical studies but no randomized clinical trials on the topic of recommendation (evidence levels IIa, IIb, III), and Grade C requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. It indicates an absence of directly applicable clinical studies of good quality (evidence level IV).

Two panel meetings were held to discuss the identified data, draft consensus statements, and finalize the updated consensus-based recommendations. Updates were made based on the identified evidence, following the principles laid out in the CheckUp guidelines.3 All authors provided input on each draft of the manuscript and approved the final version for submission.

Although 100% consensus was not attained on every recommendation, 85% of recommendations achieved 85% agreement within the expert group (supplemental Table 1).

Given the rate of development of new treatments for ITP, the consensus report leadership will review the need for updates each year. In addition to publication in professional journals, implementation of the consensus recommendations will be encouraged through distribution via patient support organizations (eg, Platelet Disorder Support Association [PDSA], UK ITP Support Association), presentations at international meetings, and through generation of an ITP treatment Web site.

### Table 2. Grading of evidence

| Grade of recommendation | Definition                                                                 | Level of evidence |
|-------------------------|---------------------------------------------------------------------------|-------------------|
| A                       | Requires ≥1 RCT as part of a body of literature of overall good quality and consistency addressing specific recommendation | Evidence levels Ia, Ib |
| B                       | Requires the availability of well-conducted clinical studies but no randomized clinical trials on the topic of recommendation | Evidence levels IIa, IIb, III |
| C                       | Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. | Evidence level IV |

Adapted from the National Guidelines Clearinghouse (www.guideline.gov).
Diagnostic approach in patients with suspected ITP

Recommendations for diagnosis of primary ITP in children and adults

1. The diagnosis of ITP is based principally on the exclusion of other causes of isolated thrombocytopenia using patient history, physical examination, blood count, and evaluation of the peripheral blood film (to exclude other hematological conditions, including hereditary thrombocytopenia and pseudothrombocytopenia). If therapy is administered, platelet count should be closely monitored for response as a diagnostic aid.

2. A complete history, physical examination, full blood count, and an expert analysis of the peripheral blood film should be evaluated at initial diagnosis (Grade C recommendation). Based on the evidence currently available, when there is isolated thrombocytopenia and no abnormal features present on physical examination or evaluation of the blood smear, a bone marrow examination is not required in the initial diagnosis (Grade B recommendation), whether or not treatment is recommended.

3. The detection of Helicobacter pylori infection, with the urea breath test or the stool antigen test, should be included in the initial work-up in appropriate geographical areas (evidence level IIa; Grade B recommendation).

4. The majority of authors routinely test for hepatitis B virus (HBV), HIV, and hepatitis C virus (HCV) in all adult patients (evidence level IIb).

5. Quantitative immunoglobulin (Ig) level testing is indicated to exclude an immune deficiency syndrome (evidence level IV; Grade C recommendation) or before treatment with IV Ig. In children, Ig level testing may be considered at baseline and should be measured in those children with persistent or chronic ITP as part of a reassessment evaluation.

6. Bone marrow examination could be appropriate in those relapsing after remission, in patients not responding to initial treatment options, where splenectomy is considered, or if other abnormalities are detected in the blood count or morphology (evidence level III; Grade C recommendation). This examination should ideally include an aspirate, biopsy, flow cytometry, and cytogenetics (evidence level IV; Grade C recommendation).

7. ITP may be classified as primary or secondary to other medical conditions present at diagnosis. Furthermore, it may be further classified as newly diagnosed (0-3 months), persistent (>3-12 months), or chronic (>12 months).

Diagnostic tools for adults and children with suspected ITP are grouped into 3 sets of recommendations (Table 3). The diagnosis of ITP can be challenging, with the differential diagnosis of thrombocytopenia being extensive (Table 4); secondary ITP needs to be excluded. A presumptive diagnosis of ITP is made when the history, physical examination, complete blood count (CBC), and examination of the peripheral blood smear do not suggest other thrombocytopenia etiologies. No “gold standard” test exists to reliably establish the diagnosis. Response to ITP-specific therapy (eg, IV Ig, IV anti-D Ig [anti-D], or steroids) supports the diagnosis but does not exclude secondary ITP, because many secondary ITPs respond to IV Ig.

Patient history

The differential diagnosis of thrombocytopenia (eg, ethanol abuse, infection, drugs, liver disease, and primary hematologic disorders) (Table 4) and secondary causes of ITP should be investigated. A previous infection has been reported in 55% of pediatric cases, and an increased ITP risk was associated with measles-mumps-rubella vaccination in children. However, in adults with newly diagnosed ITP, a case-control study found “no evidence of an increased odds of ITP after vaccination” in the previous 6 or 12 months (odds ratio, 1.0; 95% confidence interval, 0.7-1.4) (evidence level IIb).

Important historical patient information should include bleeding after previous surgery, dentistry or trauma, prior blood counts, drug and toxin exposure, recent foreign travel and vaccinations, recent infections, needle stick accidents, and prior transfusions with blood products. Incidence and degree of bleeding (eg, menstural bleeding) is important. If a diagnosis of ITP is established, contraindications to or cautions about corticosteroid therapy (eg, diabetes) should be noted. Inherited thrombocytopenia should be considered in all patients with long-standing thrombocytopenia unaffected by treatment,Child with a history of a recent infection may have persistent thrombocytopenia.

The possibility of physical abuse must be considered by emergency department staff when dealing with a patient presenting with bruising and purpura for the first time (evidence level IV).

Fatigue may be part of the ITP syndrome.

Basic evaluation

Physical examination. Physical examination should be normal aside from bleeding manifestations. Moderate or massive splenomegaly suggests an alternative cause. Constitutional symptoms (eg, fever or weight loss, hepatomegaly, splenomegaly, or lymphadenopathy) might indicate an underlying disorder (HIV, chronic liver disease, systemic lupus erythematosus [SLE], lysosomal storage disease, or a lymphoproliferative disease).

Peripheral blood count. CBC is usually normal except for isolated thrombocytopenia. Microcytic anemia from blood loss, if present, should be proportional to the amount and duration of bleeding; it may indicate iron deficiency (evidence level IV). The reticulocyte count may be used to identify the cause of anemia. Severe vitamin B12 and folate deficiency can result in thrombocytopenia.

Evaluation of peripheral blood smear. A peripheral blood smear should be evaluated by a qualified hematologist or pathologist. Pseudothrombocytopenia due to EDTA-dependent platelet agglutination should also be excluded (evidence level III).
Peripheral blood smear may demonstrate abnormalities inconsistent with ITP. For example, schistocytes in thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, or leukocyte inclusion bodies in myosin heavy chain 9–related disease). Excessive numbers of giant or small platelets may indicate an inherited thrombocytopenia.

**Bone marrow examination.** Bone marrow examination may be informative in patients with systemic symptoms, abnormal signs, or with suspicion of a different diagnosis. Bone marrow examination can be performed during consideration of splenectomy or before starting a new treatment. If performed, the bone marrow examination should include an aspirate, a biopsy, flow cytometry, and cytogentic analysis (evidence level Ib-IV) to help to distinguish ITP from lymphoproliferative disorders, myelodysplastic syndrome, or primary bone marrow disorders. In elderly patients or those not responding to corticosteroids or IVlg, NGS panels should be considered to assess for genes associated with clonal malignancy. Approximately one third of ITP patients have increased bone marrow reticulin; however, this is not correlated with disease severity, clinical features, or comorbidities, and thus should not dispute the diagnosis unless there are significant amounts of type 1 collagen seen on the trichrome stain (evidence level III).20,22

**H pylori testing.** The detection of *H pylori* infection with the urea breath test or the stool antigen test should be considered in adults with typical ITP, in those with digestive symptoms, and those from areas of high prevalence; evidence does not support routine testing in ITP patients outside of these areas (evidence level IIa).23 Serologic detection may be used, but it is less sensitive and less specific than the other tests and may produce false-positive results after IVlg therapy.

**HIV and HCV testing.** Viral testing should be performed at baseline, before giving blood products (including Ig) (evidence level IV). Thrombocytopenia associated with HIV and HCV infections may be clinically indistinguishable from primary ITP and can occur several years before other symptoms develop.24 Routine serologic evaluation for HIV and/or HCV infection in adult patients with suspected ITP is recommended, regardless of local background prevalence and personal risk factors. Controlling these infections may result in complete hematologic remission (evidence level IIa).24

### Table 3. Recommendations for the diagnosis of ITP in children and adults

| Basic evaluation in all patients | Tests of potential utility in the management of an ITP patient | Tests of unproven or uncertain benefit* |
|---------------------------------|---------------------------------------------------------------|----------------------------------------|
| Patient history                | Glycoprotein-specific antibody (can be used in difficult cases, has poor sensitivity, and is not a primary diagnostic test) | TPO level |
| Family history                 | Anti-phospholipid antibodies (including anti-cardiolipin and lupus anticoagulant) if there are clinical features of antiphospholipid syndrome | Reticulated platelets/immature platelet fraction |
| Physical examination           | Anti-thyroid antibodies and thyroid function |
| CBC and reticulocyte count     | Pregnancy test in women of childbearing potential |
| Peripheral blood film          | Antinuclear antibodies |
| Quantitative Ig level measurement† | Viral PCR for EBV, CMV, and parvovirus |
| Blood group (Rh)               | Bone marrow examination (in selected patients; refer to text) |
| HIV†                           | Direct antiglobulin test |
| HCV†                           | *H pylori*† |
| HBV                            | |

CMV, cytomegalovirus; EBV, Epstein-Barr virus; PCR, polymerase chain reaction; PTT, partial thromboplastin time; Rh, rhesus; TPO, thrombopoietin.

†These tests have no proven role in the differential diagnosis of ITP from other thrombocytopenias and do not guide patient management.

‡Quantitative Ig level measurement should be considered in children with ITP and is recommended in children with persistent or chronic ITP as part of the reassessment evaluation.

†Recommended by the majority of the panel for adult patients in the appropriate geographic setting.

### Table 4. Differential diagnoses of thrombocytopenia

| Previously diagnosed or possible high risk for conditions that may be associated with immune thrombocytopenia (eg, infections [HIV, HCV, HBV]), autoimmune/immunodeficiency disorders (CVID, systemic lupus erythematosus, or APS), and malignancy (eg, lymphoproliferative disorders) |
|---------------------------------------------------------------|
| Liver disease (including cirrhosis or portal hypertension) |

| Spleenomegaly |
|----------------|

| Drugs (prescription or nonprescription), including heparin, aminotuzumab, PD-1 inhibitors, abiciximab, valproate, alcohol abuse, consumption of quinine (tonic water), exposure to environmental toxins, or chemotherapy |

| Bone marrow diseases, including myelodysplastic syndromes, leukemias, other malignancies, metastatic disease, myelofibrosis, aplastic anemia, megaloblastic anemia, myelophthisis, and Gaucher disease |

| Recent transfusions (rare possibility of posttransfusion purpura) and recent vaccinations |

| Inherited thrombocytopenia: TAR syndrome, radioulnar synostosis, congenital amegakaryocytic thrombocytopenia, Wiskott-Aldrich syndrome, MYH9-related disease, Bernard-Soulier syndrome, type IIB WVD, or platelet-type WVD |

| Other thrombocytopenic disorders (DIC, TTP, HUS, Evans syndrome) |

This table lists frequent examples of differential diagnoses of ITP and possible alternative causes of thrombocytopenia identified by patient history. APS, antiphospholipid syndrome; CVID, common variable immunodeficiency; DIC, disseminated intravascular coagulation; HUS, hemolytic-uremic syndrome; MYH9, myosin heavy chain 9; PD-1, programmed cell death protein 1; TAR, thrombocytopenia-absent radius; TTP, thrombotic thrombocytopenic purpura; WVD, von Willebrand disease.
Quantitative Ig level testing. Baseline Ig levels (IgG, IgA, and IgM) should be measured in adults (evidence level IV) and in children. They should also be measured in children with persistent or chronic ITP during reassessment. Low levels may reveal conditions including common variable immunodeficiency (CVID).

Direct anti-globulin test. A positive direct anti-globulin test (DAT)/direct Coombs test is found in ~20% of patients with ITP; if positive, it should be followed by a haptoglobin, lactate dehydrogenase, bilirubin, and reticulocyte count to assess for hemolysis. A DAT is generally appropriate if anemia associated with a high reticulocyte count is found and if treatment with anti-D is being considered.

Blood group Rh(D) typing. This is essential if treatment using anti-D is being considered.

Tests of potential utility

Antiplatelet antibody assays: glycoprotein-specific antibody testing. Assays for antibodies to specific platelet glycoproteins are not routinely recommended. They have high specificity and low sensitivity but may be helpful in complex and difficult cases. Tests based on immunocapture, such as monoclonal antibody-specific immobilization of platelet antigens and modified antigen capture enzyme-linked immunosorbent assays, could be useful in complex cases and should be performed in reference centers. In contrast, platelet-associated IgG is unhelpful, because it is elevated in immune and nonimmune thrombocytopenia (evidence level IV). However, recent glycoprotein-specific assays have shown that the sensitivity and specificity of a positive test for diagnosis of active ITP (N = 228 patients) were 90% and 78%, respectively. Studies, which require confirmation, suggest it may be possibly prognostic for treatment response in the future.

Anti-phospholipid antibodies. Anti-phospholipid antibodies (APLAs), including anti-cardiolipin antibodies and lupus anticoagulant, can be found in up to 46% of otherwise typical adults with ITP, although most studies report rates of 25% to 30%. APLAs do not appear to affect the response to ITP treatment. Routine testing is not recommended in the absence of symptoms of antiphospholipid syndrome (e.g., venous/arterial thrombosis or history of fetal loss), but it may be useful if there is concern about thrombosis or other aspects of antiphospholipid syndrome.

Anti-nuclear and extractable nuclear antigen antibodies. A positive antinuclear antibody (ANA) test is present in 9% of children and 33% of adults with ITP and may be a predictor of chronicity (evidence levels IIb, III); hydroxychloroquine may be an effective treatment if ANAs are present, especially in young women. ANA testing can be considered before splenectomy because of the increased risk for thrombosis after splenectomy.

Anti-thyroid antibody and thyroid function testing. ITP was associated with clinical hyperthyroidism in 8% to 14% of patients followed in a longitudinal study. Other patients developed antibodies to thyroglobulin with hyper- or hypothyroidism. Mild thrombocytopenia can occur in patients with hyperthyroidism (reduced platelet survival) or hypothyroidism (possible decreased platelet production), often resolving with restoration of the euthyroid state. Antibodies to thyroglobulin, free T4, and thyroid-stimulating hormone may be measured to identify at-risk patients.

Testing for other acute and persistent infections. There has been anecdotal association between vaccination and ITP; a prospective case-control study found no increased incidence of ITP following vaccination (evidence level IIb). Acute viral infections and some vaccinations (with live attenuated virus) have been associated with (usually transient) thrombocytopenia. Some acute or persistent infections (e.g., parvovirus, Epstein-Barr virus, and cytomegalovirus) can cause and perpetuate thrombocytopenia.

Thrombopoietin level. Thrombopoietin (TPO) levels are generally normal in ITP patients and markedly elevated in thrombocytopenia patients as a result of bone marrow failure.

Reticulated platelets/immaute platelet fraction. Reticulated platelets/immaute platelet fraction are thought to reflect platelet production, and these values are elevated in most patients with ITP. However, these assays are not standardized yet and have limited availability.

Coagulation tests. The partial thromboplastin time (PTT), fibrinogen level, and d-dimer tests might be helpful in excluding chronic disseminated intravascular coagulation (DIC) or other coagulopathies. Testing for ADAMTS13 deficiency may be needed to exclude thrombotic microangiopathies.

Classification of ITP

ITP may be classified as primary or secondary; this article focuses only on primary ITP. In many cases, patients with primary or secondary ITP are treated similarly. However, if ITP is secondary to an underlying disease (e.g., HCV, HIV, or a lymphoproliferative disease), treatment may focus on this instead of the ITP.

ITP can also be classified by disease duration: newly diagnosed (0-3 months), persistent (>3-12 months), or chronic (>12 months). The term “refractory” has been used to refer to patients who failed splenectomy, but given the declining rate of splenectomy in ITP, it will not be used here.

ITP in adults

The treatment landscape has changed considerably; rituximab, eltrombopag, avatrombopag, and romiplostim are well studied, and high-dose dexamethasone may be an alternative to prednisone. Splenectomy is now recommended only after failure of medical therapies and depending on patient age and comorbidities. Here, an updated comprehensive approach to treatment is provided with evidence published since 2010 (Figure 1; Table 5). Treatment options are listed per the authors’ assessment of clinical benefit. Treatment is divided into the following categories: initial treatment, subsequent treatment, and patients failing multiple treatments.

Treatment choice is impacted by cost, financial resources of the patient, or the publicly funded health care system, national licensing and availability, and country-specific treatment guidelines. The higher cost of newer treatments is counterbalanced by the fact that some new treatments are not immunosuppressive, have undergone rigorous RCTs, have high efficacy, and may lead to periods of treatment-free remission.

Who should be treated?

Treatment should always be tailored to the patient, because many factors contribute to treatment decisions. Impacting management
decisions are the extent of bleeding, age, comorbidities predisposing to bleeding, complications of specific therapies, activity and lifestyle, fatigue (see “Quality of life of adults with ITP”), tolerance of side effects, need for interventions with a bleeding risk, accessibility of care, patient expectations, patient worry or anxiety, and patient need for non-ITP medications that may create a bleeding risk. Female sex, exposure to nonsteroidal anti-inflammatory drugs (NSAIDs), platelet count <20 × 10⁹/L, and exposure to anticoagulant drugs were associated with bleeding at diagnosis;⁵⁰ bleeding and infection contribute equally to mortality.⁵¹ Although bleeding risk is rarely related to any distinct threshold platelet count, bleeding risk appears to increase when platelets are < 20 × 10⁹/L.⁵² Based on this and the consensus of the authors, treatment is rarely indicated in patients with platelet counts > 20 × 10⁹/L in the absence of bleeding due to platelet dysfunction or another known or unknown hemostatic defect, trauma, surgery,¹⁰⁰ clearly identified comorbidities for bleeding, mandated antiplatelet or anticoagulation therapy, or fatigue or other nonhemorrhagic complications of ITP, as well as in persons whose profession or lifestyle predisposes them to trauma. Patient preference must be considered when discussing treatment options.

Several case series reported successful use of eltrombopag or romiplostim as a “bridging” therapy to increase platelet counts prior to surgery or another procedure (evidence level III).⁵²-⁵⁴ Consensus-based recommendations for patients with ITP undergoing surgery are presented in Table 6.

Figure 1. Overview of therapies for the treatment of adult ITP. The evidence available for medical therapies is indicated.

Goals of therapy

Recommendations for treatment goals

1. Treatment goals should be individualized to the patient and the phase of the disease.
2. Treatment should prevent severe bleeding episodes.
3. Treatment should maintain a target platelet level >20-30 × 10⁹/L at least for symptomatic patients (because risk for major bleeding increases below this level).
4. Treatment should be with minimal toxicity.
5. Treatment should optimize health-related quality of life (HRQoL).

Together with patient-individual and disease phase-specific treatment, patients must be educated on clinical treatment goals and reassured so that they can continue normal activities. The clinical goals should be to resolve bleeding events or to prevent severe bleeding through providing adequate hemostasis. The platelet count should be improved to attain a minimum of 20 to 30 × 10⁹/L, but there is no need to normalize the platelet count; however, this level may not be appropriate for patients who are active or older than 60 years of age (several studies have shown increased rates of bleeding, thrombosis,
Table 5. Therapies for the treatment of ITP

| Clinical situation                                      | Therapy option                      |
|--------------------------------------------------------|-------------------------------------|
| Initial treatment of newly diagnosed ITP               | Corticosteroids                     |
|                                                        | Dexamethasone                       |
|                                                        | Methylprednisolone                  |
|                                                        | Prednisolone                        |
|                                                        | IVIg                                 |
|                                                        | Anti-D (licensed and available for ITP in only a few countries) |
| Subsequent treatment                                   | Medical therapies                   |
|                                                        | Medical therapies with robust evidence |
|                                                        | Rituximab                           |
|                                                        | TPO-RAs: eltrombopag, avatrombopag, romiplostim |
|                                                        | Fostamatinib                        |
|                                                        | Medical therapies with less robust evidence |
|                                                        | Azathioprine                        |
|                                                        | Cyclophosphamide                    |
|                                                        | Cyclosporine A                      |
|                                                        | Danazol                             |
|                                                        | Dapsone                             |
|                                                        | Mycophenolate mofetil               |
|                                                        | TPO-RA switch                       |
|                                                        | Vinca alkaloids                     |
|                                                        | Surgical therapies                  |
|                                                        | Splenectomy                         |
| Treatment of patients failing multiple therapies       | Accessory splenectomy               |
|                                                        | Alemtuzumab                         |
|                                                        | Combination of initial and subsequent therapies |
|                                                        | Combination chemotherapy            |
|                                                        | Clinical trials                     |
|                                                        | HSCT                                |
|                                                        | Splenectomy, if not already performed |
|                                                        | Supportive care                     |

Initial treatment of newly diagnosed patients

Initial treatments for adults newly diagnosed with ITP are presented in supplemental Table 2.

Corticosteroid therapy. Corticosteroids remain the standard initial treatment of newly diagnosed patients and should be used for a limited time. Corticosteroids have multiple beneficial hematostatic effects on platelets by decreasing platelet clearance and increasing platelet production. Additionally, they may reduce bleeding, independent of the platelet count increase, via a direct effect on blood vessels and increasing platelet production. Additionally, they may reduce bleeding, independent of the platelet count increase, via a direct effect on blood vessels and increasing platelet production.1 Although the consensus panel believed that some patients were able to maintain a platelet response to a daily dose of prednisolone ≤ 5 mg, the side effects of corticosteroids outweigh their benefits in the long-term.1

PREDNISONE AND DEXAMETHASONE. There are multiple small trials on prednisone and dexamethasone with various outcomes.53-69 In a meta-analysis of high-dose dexamethasone vs prednisone,
Table 6. Consensus-based recommendation for target platelet counts for surgery or medical therapy in adults

| Type of surgery                                      | Target platelet count, × 10^9/L |
|------------------------------------------------------|---------------------------------|
| Dental prophylaxis (descaling, deep cleaning)        | ≥20 to 30                       |
| Simple extractions                                   | ≥50                             |
| Complex extractions                                  | ≥50                             |
| Regional dental block                                | ≥30                             |
| Minor surgery*                                       | ≥50                             |
| Major surgery                                        | ≥80                             |
| Major neurosurgery                                   | ≥100                            |
| Splenectomy                                           | See “Subsequent therapy: surgical” |
| Obstetrics                                            | See “Thrombocytopenia presenting during pregnancy” |
| Single antplatelet agent or anticoagulant (ie, 1 antplatelet agent, warfarin, or TSOAC) | ≥30 to 50                      |
| Dual antplatelet agent or anticoagulant (ie, 2 antplatelet agents or 1 antplatelet agent plus warfarin or TSOAC) | ≥50 to 70                      |

Evidence level IV. Adult patients with ITP considered to be at “typical” bleeding risk from surgery. Target platelet count depends on the clinical situation and urgency and need for procedure. TSOAC, target-specific oral anticoagulants. *Cataract surgery with laser technique has no bleeding risk.

there was no difference in platelet count response at 6 months; however, high-dose dexamethasone led to faster responses without additional toxicity. Acyclovir may be given with dexamethasone to minimize the potential for herpes virus reactivation (evidence level IV).

Dexamethasone plus Rituximab. Since 2010, 5 studies (1 in children), including 2 large RCTs, have assessed the efficacy of rituximab in combination with dexamethasone. Additionally, a large meta-analysis on rituximab plus standard of care published in 2015 showed that adding rituximab may increase the response rate earlier; however, after 6 to 12 months, there is limited evidence for a sustained response. The panel believed that the potential benefit of adding rituximab to corticosteroids did not warrant the added toxicity and costs but that with further study this regimen may be proven to be the optimal way of using these 2 therapies.

Methylprednisolone. High-dose methylprednisolone was used in various regimens to treat patients failing first-line therapies, with 80% response rates; however, maintenance therapy with oral corticosteroids may be required as a result of the short-term response (evidence level IV). There are no new data since 2010 to recommend methylprednisolone over dexamethasone or prednisone.

IVlg. Seven studies assessing IVlg were identified. IVlg as a standard ITP therapy is well documented. Newer research focused on optimizing delivery of IVlg infusions to reduce the burden of treatment and HRQoL or trialing different formulations or rates. IVlg 10% is as effective as IVlg 5%, with response rates ranging from 72.2% to 80.7% (evidence level IIa-IIb). Adverse events (AEs) were comparable to those seen for IVlg 5% (evidence level IIa-IIb).

Several studies have examined the relationship between IVlg responses and the type of antplatelet antibody. Two have found a reduced IVlg response in patients with only anti–GPIIb-IX antibodies. In 1 study, IVlg therapy (0.4 g/kg per day for 5 days) in treatment-naive adults with severe ITP resulted in responses (platelet count ≥30 × 10^9/L) in 36.4% of patients with anti–GPIIb-IX antibodies and in 80% of those negative for anti–GPIIb-IX autoantibodies. Although anti–GPIIb-IX antibodies may predict poor response to IVlg (evidence level IIb), this finding has not been confirmed by other studies. Moreover, these tests are not readily available, and most patients have multiple antibodies; rarely do they have only anti–GPIIb-IX antibodies.

Subcutaneous Ig does not appear to be as effective as IVlg in ITP. IV anti-D. In addition to the previous studies, 1 small study (20 patients) evaluated anti-D treatment (60 µg/kg) in adults with ITP. In newly diagnosed patients, the overall response rate was 85%, with a median duration of remission of 25 days; however, administration of anti-D was associated with chills, pyrexia, a decrease in hemoglobin count, and an increase in bilirubin, with clinical and laboratory evidence of hemolysis in all patients (evidence level III). This drug should be used with caution in patients with active autoimmune hemolysis and anemia. IV anti-D carries a black box warning for a risk for intravascular hemolysis in ITP leading to death, anemia, multisystem organ failure, and acute respiratory distress syndrome, as well as serious complications, including severe anemia, acute renal insufficiency, renal failure, and DIC. Administering IV anti-D with steroid premedication greatly minimizes the side effects indicated. IV anti-D is not available in Europe.

Emergency treatment

Recommendations for life-threatening bleeding

1. A combination of initial treatments, including IV corticosteroids and, usually, IVlg, should be used in emergency situations in which there is an urgent need to increase the platelet count within 24 hours (Grade C recommendation). Platelet transfusions may be helpful and must not be postponed in cases of life-threatening bleeding, especially intracranial hemorrhage (ICH).

2. In the case of life-threatening bleeding and the absence of a significant response to IVlg and platelet transfusion in a patient on corticosteroids, the use of a TPO-RA should be considered.

3. Additional options may include IV anti-D, vincristine or vinblastine, antifibrinolytics in combination with other initial therapies (Grade C recommendation), and, rarely, emergency splenectomy.

No study was found reporting on treatments aimed at urgently increasing platelet counts in patients requiring urgent surgery, those at high risk for bleeding, or those with active central nervous system, gastrointestinal, or genitourinary bleeding.

Although changing from corticosteroids to IVlg or anti-D alone may be effective in emergency settings, adding either to corticosteroids may be appropriate for the emergency treatment of patients with uncontrolled bleeding. High-dose methylprednisolone may also be useful. Other therapies that work rapidly include platelet transfusion, possibly combined with IVlg, and emergency splenectomy. Some evidence shows a rapid (peak effect in 7-9 days) response to vinca alkaloids.
Although TPO-RAs take ≥5 days to initiate a response, and rituximab usually takes 3 to 4 weeks, early administration of either might be considered, especially in patients who are not surgical candidates or who have major contraindications to other therapies. Also, because almost all other treatments will be short-lived, administration of these agents may limit the need to revisit the emergency department 2 weeks later.

DEFINITION OF LIFE-THREATENING BLEEDING. Patients presenting with severe bleeding manifestations, particularly if the platelet count is ≤20 × 10^9/L, demand immediate treatment. Definition of bleeding severity is largely a subjective judgment by the clinician, but the use of a standardized bleeding assessment tool may represent a general guide. For example, Khellaf et al used a very simple score based on subjective judgment of external bleeding manifestations at onset to decide between treatment based on corticosteroids only or corticosteroids plus IVIG. An International Working Group (IWG) proposed a more elaborate standardized bleeding assessment tool in which 3 distinct domains (skin, visible mucousae, organ) were scored based on the worst manifestation.

General measures. These include cessation of drugs reducing platelet function, control of blood pressure, inhibition of menses, and efforts to minimize trauma (evidence level IV). However, there may be instances in which oral anticoagulation (eg, in patients with some prosthetic heart valves, atrial fibrillation, or with coronary stents) is required, and this necessitates raising the threshold platelet count for treatment. In patients with reduced renal function, hemostasis may be improved with estrogens or desmopressin and by maintaining hemoglobin at ≥10 g/dL.

Platelet transfusions with or without IVIG. Platelet transfusion in ITP has been poorly studied but is widely recommended in bleeding patients failing other therapies. Platelet transfusion increases the posttransfusion platelet count by >20 × 10^9/L in 42% of bleeding ITP patients and may reduce bleeding. In a retrospective study of 40 patients (evidence level IIb), concurrent administration of platelet transfusions and IVIG was associated with bleeding resolution, rapid restoration of adequate platelet counts, and minimal side effects (evidence level III/IV). This combination is widely used, albeit not well substantiated. Similarly, platelet bolus vs continuous infusion is not well studied, but giving a bolus, followed by continuous infusion, seems appropriate in situations in which increasing the platelet count is urgent, especially if the bolus increases the platelet count.

Vinca alkaloids. Weekly IV doses of vincristine (1-2 mg for 2-4 weeks) or vinblastine (10 mg for 1-3 weeks) are associated with rapid responses of 71% at 7 days and 68% at 1 month in patients with ITP. Unfortunately, these high rates of response are accompanied by a low rate of durable response (28%) and significant toxicity. However, when combined with other agents, vinca alkaloids may be useful in patients requiring emergency treatment (evidence level IIb). Repetitive use is commonly associated with peripheral neuropathy, which may favor vinblastine.

Emergency splenectomy. See “Subsequent therapy: surgical.”

Antifibrinolytics. Antifibrinolytic agents (eg, oral or IV tranexamic acid and ε-aminocaproic acid) may be useful in preventing recurrent bleeding in patients with severe thrombocytopenia; however, the efficacy has not been evaluated by a randomized trial in ITP patients. A recent Cochrane analysis of patients with many types of thrombocytopenia was inconclusive. Tranexamic acid (15 to 20 mg/kg every 8 hours orally) and ε-aminocaproic acid (1-5 g every 4-6 hours [maximum dose, 24 g/d]) may be useful in certain dental or surgical procedures or if there is ongoing or a substantial risk for bleeding. Use of these agents also increases the risk of thrombosis.

Emergency treatments that are not indicated. Plasmapheresis and recombinant factor VIIIa are not recommended.

Subsequent treatment options for adult patients with persistent and chronic ITP

Most adult patients relapse upon cessation of steroid treatment. Although few patients may be maintained on daily low doses of steroids (eg, ≤2.5-5 mg prednisone) for prolonged periods of time without incurring major side effects, subsequent therapy is indicated for most other patients. Probably the most consistent and prevalent error in ITP management is overuse and reliance on steroids. Currently, no study has addressed the correct sequence of subsequent therapies; as such, the panel presents the following consensus-based recommendations.

Recommendations for subsequent therapy strategy

1. There are many medical therapy options with few AEs.
2. Not all therapies are available in all countries; thus, the recommendations should be modified based on available resources and patient preference.
3. Some medical options may require ongoing continued treatment.
4. Up to one third of patients may remit in 1 year, and up to 80% may remit in 5 years. If possible, splenectomy should be deferred for ≥1 year to allow for remission.

Since 2010, the main changes are in the use of rituximab, the TPO-RAs (eltrombopag, avatrombopag, and romiplostim), and fostamatinib, for which numerous studies have been published; the main evidence is described here. Furthermore, splenectomy is dealt with as a separate section (see “Subsequent therapy: surgical”). Physicians should make individual judgments about the nature of subsequent treatments based on the patient’s profile (bleeding history, comorbidities, and compliance), patient preference, and availability of drugs.

The main goal of subsequent treatment is to attain a sustained increase in the platelet count that is considered hemostatic for the individual patient while minimizing AEs and allowing for the possibility of attaining a remission.

The concept of remission in ITP has not been rigorously defined. In several articles it has been defined as a platelet count ≥30 × 10^9/L in the absence of treatment. It occurs in up to 85% of ITP patients without splenectomy after 5 years, and in 32% of ITP patients within 1 year if treated with romiplostim within the first 6 months of diagnosis, and in 28% of patients with chronic ITP treated with romiplostim for >6 months. For this consensus, remission will be regarded as a platelet count ≥30 × 10^9/L in the absence of any ITP-specific treatment.

Available treatment modalities have different mechanisms of action and can be broadly categorized into those that are given only
once (or for only 1 course) and are intended to induce a long-term response (rituximab, splenectomy) and those that need continued or chronic administration (low-dose corticosteroids, immunosuppressive agents, TPO-RAs). Patients on agents in the latter category may improve at any time, but who will improve and when is unpredictable (supplemental Table 3).

Subsequent therapy: medical

Medical therapies with robust evidence

1. TPO-RAs (eltrombopag, avatrombopag, romiplostim) have provided excellent responses (>60%) in splenectomized and nonsplenectomized patients (Grade A recommendation, evidence level I). Response to continued TPO-RAs persists for up to 6 to 8 years and often allows other ITP therapy to be reduced or discontinued. Cessation of treatment will lead to the return of thrombocytopenia in most cases, but some patients (10%-30%) may achieve a durable response after TPO-RAs are tapered and withdrawn.

2. Evidence from a systematic review of multiple uncontrolled trials and RCTs shows a response to rituximab in 60% of patients. Long-term durable responses occur in 20% to 25% of adult patients (Grade B recommendation, evidence level IIa). Prior to treatment, hepatitis B status should be determined, and vaccination against encapsulated gram-positive bacteria should be given (Grade C recommendation, evidence level IV).

3. Fostamatinib offers an alternative mechanism for reducing platelet destruction; it may provide response rates of 43% but stable responses of only 18%.

TPO-RAs: romiplostim, eltrombopag, avatrombopag

TPO-RAs increase platelet production (supplemental Table 3). Romiplostim and eltrombopag are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of adults (and children, see below) with chronic ITP who have had an insufficient response to corticosteroids, Igs, or splenectomy. Romiplostim and eltrombopag are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of adults (and children, see below) with chronic ITP who have had an insufficient response to corticosteroids, Igs, or splenectomy. Avatrombopag has only recently (27 June 2019) been approved by the FDA for adult patients with chronic ITP who have had an insufficient response to a previous treatment. Romiplostim is administered at an initial dose of 1 mg/kg per week subcutaneously, with dose adjustments up to 10 mg/kg per week according to platelet response. Avatrombopag is administered at an initial dose of 25 or 50 mg/d, depending on patient age, Asian ancestry, and presence of hepatic impairment, up to a maximum of 75 mg/d. Avatrombopag is administered initially as 1 20-mg pill daily with dose increases up to 40 mg/d, depending on subsequent platelet counts.

Due to their mechanism of action, TPO-RAs are considered a maintenance therapy. Upon cessation of treatment, many patients return to lower platelet counts (10% transiently falling below baseline platelet counts); however, nearly one third of newly diagnosed patients and ~15% to 30% of chronic patients are able to eventually discontinue treatment successfully, for various periods. In studies, most AEs were reported as mild. These drugs are associated with a possible increase in bone marrow reticulin fibrosis, which has been a concern, but the risk of clinically meaningful fibrosis appears to be very low. Bone marrow fibrosis has been assessed in prospective studies with romiplostim and eltrombopag; it was found to be increased by treatment in 6.9% of patients on romiplostim and in 3.8% of those on eltrombopag. Most patients were able to remain on treatment; fibrosis was reversed in those who stopped.

Recent studies have shown no significant increased rate of cataracts and a low (<15%) rate of mild liver function test abnormalities with eltrombopag; however, 3% of patients have had to discontinue the drug for this reason. Bone marrow examinations are not mandatory prior to initiating TPO-RAs, but regular monitoring of blood counts is needed. Bone marrow biopsy should be performed if there is no response to treatment within the expected timeframe or if the diagnosis is not certain.

TPO-RAs can be associated with arterial and venous thrombosis. In the long-term studies, 6% of patients developed arterial or venous thrombosis. However, when directly compared with placebo, none of these drugs resulted in an increased rate of thromboembolism, recognizing that the risk of thromboembolism is increased in ITP patients not so treated. However, there is some evidence that thrombotic events are higher in ITP patients on romiplostim, especially those older than 60 years.

Romiplostim. Many studies on romiplostim have been published (evidence levels Ib, IIb, and III). Compared with placebo, romiplostim has been shown to significantly increase and maintain platelet counts. Response rates of 74% to 96% have been reported, with some studies showing no differences in splenectomized patients and others reporting lower responses (evidence level IIb). Responses were shown to be slightly higher in patients ≥65 years old vs <65 years old and are achieved after 1 week of treatment and time to response is shorter with a 3-μg/kg dose compared with a 1-μg/kg dose (1 vs 2 weeks). A lengthened dose interval of romiplostim from once weekly to once every 2 weeks has not been shown to be effective (evidence level III). Responses remained stable for ≥3 weeks in 82% of patients without a dose change and patients had a platelet response > 50 × 10^9/L on a median of 92% of visits; evidence level III). Treatment-free remissions occurred in 28% of patients after a median of 1.8 years and was more likely in splenectomized patients than in those who had failed previous treatments (evidence level III).

Use of rescue medication (9% to 47%) varied among studies: it appeared to be used more frequently in splenectomized patients and declined significantly over time on romiplostim treatment. Concomitant Ig use was reduced by 5.31-fold in 1 study (evidence level IIb and was reported to be rarely used in another (evidence level III). Additionally, concurrent ITP treatments were discontinued or reduced in 54% to 100% of patients. Bleeding events have been shown to decrease. Adverse drug reactions were shown to be comparable with standard of care or placebo with a rate of thromboembolic events of 3% to 6.5%, the same as placebo. Bone marrow reticulin was reported in 4 to 17 patients in studies; an increase of bone marrow reticulin by ≥2 grades was reported in 6.9% of patients in a phase 4 study. 

Romiplostim should be discontinued if the platelet count does not increase sufficiently after 4 weeks of treatment at the maximum
dose of 10 μg/kg per week. If response to romiplostim is lost, testing for an anti-romiplostim antibody should be considered.

Alternative dosing strategies. Although the recommended starting dose is 1 μg/kg per week, escalation to the maximum dose of 10 μg/kg could take 10 weeks. The average weekly romiplostim dose in most studies is 3 to 5 μg/kg, and 1 study has used 3 μg/kg as the initial dose. Suboptimal platelet response may be improved by adding low doses (2.5-5 mg) of prednisone to romiplostim.

ELTROMBOPAG. Several studies and 1 meta-analysis on eltrombopag have been published since the previous consensus recommendations.

Eltrombopag is administered orally ≥2 hours before or 4 hours after products containing polyvalent cations (eg, calcium-containing dairy products). This is due to its nature as a chelator. If there is no response after 4 weeks of treatment at the maximum dose, treatment with eltrombopag should be discontinued.

Eltrombopag carries a black box warning for hepatic decompensation in patients with chronic hepatitis C and a risk for hepatotoxicity. Liver tests and CBCs should be performed regularly throughout treatment with eltrombopag.

Persistent and newly diagnosed ITP. Use of eltrombopag was shown to be effective in a retrospective study of 220 patients with newly diagnosed or persistent ITP. At 15 months, responses occurred in 90% of patients, with complete responses achieved in 75.9% (platelet count ≥30 × 10^9/L). No differences in responses were seen between the phase of ITP, but there was a trend toward better responses in newly diagnosed patients (93.3% responses and 86.7% complete responses). Responses in persistent ITP (83.3% responses and 80.0% complete responses) and chronic ITP (79.4% responses and 73.1% complete responses) were similar (evidence level III).

Chronic ITP. Elnrombopag has been well studied in patients with chronic ITP since the previous consensus recommendations. Elnrombopag has been used at a starting dose of 50 mg daily, as well as 12.5 mg or 25 mg in 1 trial. Response rates vary but have been reported to range from 50% to 88.8%.

Eltrombopag is associated with a decrease in bleeding rates across studies, with a 26-fold greater chance of achieving platelet counts ≥50 × 10^9/L (P < .001) over placebo. A median platelet response rate of 75.2% over 15 months has been reported, although platelet values have been shown to return to baseline values 2 weeks after treatment cessation. Spleenectomy status, baseline platelet count, concomitant ITP treatments, and number of previous ITP treatments do not appear to have any effect on response rates.

Longer-term use of eltrombopag (EXTEND study). Elnrombopag has been shown to be effective in the long term in the open-label EXTEND study conducted in 302 ITP patients. Elnrombopag led to an increase in median platelet counts to ≥50 × 10^9/L by week 2, which was sustained throughout the median treatment period of 2.37 years (range, 2 days to 8.76 years). Responses were achieved in 85.8% of patients (platelet count ≥50 × 10^9/L at least once in the absence of rescue therapies), and 52% achieved continuous responses (≥25 weeks). Low platelet counts (<15 × 10^9/L), more previous therapies, and/or splenectomy led to slightly lower responses. Bleeding symptoms decreased from 57% to 16% at 1 year. Moderate to marked bone marrow reticulin fibrosis was observed in 2 patients (1.7%) (evidence level III).

Alternative dosing regimen. Although the prescribed dose is 25 to 75 mg/d, with the daily dose being decreased for platelet counts ≥200 × 10^9/L, an alternative dosing algorithm has been reported in which 75-mg dosing is used in patients without liver dysfunction or Asian ancestry, and the frequency of the 75 mg/d dose is decreased, often to twice a week.

Discontinuation and sustained responses. In 1 study, eltrombopag led to complete responses in 201 of 260 patients (evidence level III). Of these, 80 discontinued therapy, and 26 of the 49 evaluable patients (53%) maintained their response for ≥6 months. Patients had a median time from ITP diagnosis of 46.5 months, with a median of 4 previous treatments, and 42% were splenectomized.

AVATROMBOPAG. Avatrombopag is another TPO-RA that was very recently approved by the FDA for the treatment of chronic ITP in adults. Like eltrombopag, avatrombopag binds to the transmembrane region of the TPO receptor and activates signal transduction pathways leading to increased platelet production. The drug is administered orally, has no interactions with food or cations, does not require monitoring of liver functions, and is three- to four-fold more potent than eltrombopag in stimulating an increase in platelets in healthy volunteers. Phase 2 studies in humans showed that 93% of adult ITP patients had a platelet response (platelets increasing to ≥50 × 10^9/L) 7 days after starting a 20-mg/d dose vs 7% of those on placebo. Responses were maintained for 6 months in an extension study. In the subsequent phase 3 study (NCT014339768), adults with chronic ITP were randomized to 20 mg of avatrombopag (32 subjects) or placebo (17 subjects) for 24 weeks; the median cumulative number of weeks with a platelet response ≥50 × 10^9/L was 12.4 for avatrombopag and 0.0 for placebo (P < .0001). Platelet responses were rapid (66% by day 9) and were maintained for >12 months in an extension study. Efficacy in children has not yet been established. Dose changes are made by increasing the 20-mg starting dose to 40 mg/d or reducing dose frequency.

Rituximab. Long-term data for rituximab have become available since 2010 (supplemental Table 3). A meta-analysis of 5 trials revealed that complete responses were more likely with rituximab than with standard of care; thus, rituximab can improve platelet count responses at 6 months in ITP patients. The meta-analysis showed that rituximab was not associated with reductions in bleeding or an increase in infections. The 5-year outcomes of rituximab at the standard dose were assessed in 376 adults; this study revealed that 215 patients (57%) attained a remission (144 [38%] complete; 71 [19%] partial). Of the initially treated adults, only 38% maintained remission at 1 year, and 21% maintained remission at 5 years. No difference in projected outcomes with respect to splenectomy was found, although there was a tendency for splenectomized patients to relapse earlier than nonsplenectomized patients. In adults with responses lasting ≥1 year, relapse rate in partial responders was 53% compared with 31% in complete responders (P < .1) (evidence level III). In another study, chronic ITP patients who had not responded to corticosteroids or dexamethasone underwent splenectomy or rituximab therapy at a standard dose; no significant differences in the rate of sustained response to rituximab or splenectomy were observed. There was a propensity for younger patients to...
have been treated with splenectomy and older patients with rituximab (evidence level IIb).162

In other studies included here, rituximab has primarily been used at a dose of 4 infusions of 375 mg/m²2,163-169 although 3 studies have assessed higher dosing schedules and 2 studies have assessed lower dosing schedules (see “Alternative dosing”).166,170-173 Studies indicate that response rates vary from ~60% to 80%166,169; lower response rates appear to be associated with an increased number of failed previous therapies and long duration of disease.163,164 Patients with a shorter duration of disease were statistically significantly more likely to achieve a response (P = .082); patients <40 years old and females were more likely to achieve a complete response (P = .025 and P = .009, respectively).164 Previous splenectomy does not appear to affect the response rate (evidence level III), although there is a tendency to relapse earlier.165 One study showed that responses were better in patients with concomitant corticosteroids compared with rituximab alone (evidence level III).165 Time to relapse has been reported as 36 weeks (evidence level Ib),167 and lasting responses have been reported as 29% at 24 months; a sustained response at 1 year was significantly associated with ITP duration <1 year (P = .02) and a previous transient response to corticosteroids (P = .05) (evidence level III).168 Rituximab may be a good therapeutic option for the treatment of SLE-associated and corticosteroid-dependent ITP.174

CONTRAINDICATIONS AND LONG-TERM SAFETY. Rituximab carries a black box warning for fatal infusion reactions, severe mucocutaneous reactions, HBV reactivation, and progressive multifocal leukoencephalopathy.175,176 Patients should be screened for HBV infection prior to rituximab administration; those with evidence of prior resolved HBV infection should be monitored during and for several months following rituximab treatment, whereas those with active infection needing rituximab should receive concurrent antiviral treatment.175,176

AEs associated with rituximab in ITP are usually mild or moderate, with a very low incidence of infections of variable severity.76,167,168,177 Previously, there were reports of >50 cases of progressive multifocal leukoencephalopathy (JC virus infection) associated with rituximab treatment in patients with lymphoma, as well as 2 patients with SLE and ITP.1 These cases tended to occur in patients who were heavily immunosuppressed and on combination treatments.

ALTERNATIVE DOSING. Alternative dosing schedules (1000 mg on days 1 and 15168,170,171 and 100 mg weekly for 4 weeks172,173) have been used and showed response rates >50% (evidence level III).173,178

RITUXIMAB AND DEXAMETHASONE. See “Initial treatment of newly diagnosed patients: dexamethasone plus rituximab.”

RITUXIMAB AND VACCINE EFFECT. Immunological responses to polysaccharide and conjugated vaccines appear to be impaired in ITP patients who have undergone treatment with rituximab until B-cell return for ≥6 months (evidence level III).179

RITUXIMAB AND HYPOGAMMAGLOBULINEMIA. Repetitive use of rituximab may cause hypogammaglobulinemia. Ig levels should be monitored in patients receiving repetitive dosing.

Fostamatinib. Fostamatinib is a small molecule spleen tyrosine kinase inhibitor that was approved by the FDA in April 2018 for treatment of adults with chronic ITP who have had insufficient responses to a previous treatment.180 Two double-blind RCTs in patients who had failed splenectomy, TPO agents, and/or rituximab, and with a median duration of ITP of 8.5 years, have shown that fostamatinib, at an initial dose of 100 mg twice daily (frequently increased to 150 mg twice daily in nonresponders), results in an overall response (platelets ≥50 × 10^9/L) rate of 43% but with a median stable response (platelets ≥50 × 10^9/L for 4 of 6 weeks) of only 18% vs 2% of those on placebo (P = .0003). However, the time to response was short, occurring at a median of 15 days (evidence level Ib).181 Patients previously treated with a TPO-RA had a 17% stable response rate.181 More than half of the responders maintained a response on long-term treatment.182 The most common AEs leading to dose reductions were hypertension and diarrhea.181 If no response is seen after 12 weeks, the drug should be discontinued (supplemental Table 3).180

Medical therapies with less robust evidence

1. Immunosuppressive agents (including mycophenolate mofetil [MMF], cyclosporine A, and azathioprine) may be used in patients failing other therapies. Danazol and dapsone are “corticosteroid-sparing” agents that may be particularly useful in some patients (eg, those in whom splenectomy is contraindicated or if other agents are unavailable) (Grade B recommendation, evidence level IIa/IIb).

2. Vinca alkaloids are not a chronic therapy option because of neurological toxicity.

Therapies are presented here in alphabetical order; only new data found in the literature search are presented. For many of these agents (eg, cyclosporine A, mycophenolate), there is anecdotal evidence that the addition of corticosteroids or TPO-RA may enhance the response.

AZATHIOPRINE. Limited published data were found since 2010. A retrospective study assessing treatment patterns in ITP patients in Sri Lanka could not demonstrate a significant response to azathioprine (evidence level III).183 Azathioprine has less of a role in patients who could try a TPO-RA or rituximab (supplemental Table 3).

CYCLOSPORINE A. Cyclosporine A (2.5-3 mg/kg per day) increases the platelet count as a single agent or in combination with prednisolone. In some patients, the side effect profile restricts its use (Grade B recommendation). Because of its side effect profile, the panel preferred mycophenolate. No new data were found (supplemental Table 3).

CYCLOPHOSPHAMIDE. No new data were found (supplemental Table 3).

DANAZOL. One multicenter RCT compared the safety and efficacy of recombinant human TPO (rhTPO) with danazol in patients with persistent ITP; rhTPO plus danazol was more effective than danazol alone and had a slightly shorter time to response (evidence level Ib) (supplemental Table 3).184 In another study of 319 Chinese ITP patients treated with danazol, with or without corticosteroids, the overall response rate was 65%; of the 103 patients treated with danazol alone, 63% attained remission.185

DAPSONE. Two studies have reported on dapsone treatment in ITP patients. Response rates of 55% with a median time to response of 1 month were reported in 20 patients treated with dapsone as a salvage therapy for ITP that had relapsed or failed steroid or
rituximab treatments. In all responders, concomitant therapies were discontinued; dapsone was given for a median of 31 months in responders, and responses lasted for 42 months (evidence level III). A retrospective analysis reported an overall response rate of 66%, including 24% complete responses, with dapsone in patients with ITP. Response was maintained by 81% of responders after interruption of treatment, for a median of 26 months (evidence level III) (supplemental Table 3).

MMF. Two studies have reported on the use of MMF (evidence level III), the studies appear to show that a long duration of daily dosing is required for achieving a response and that MMF can be used effectively many years after an initial ITP diagnosis (supplemental Table 3).

VINCA ALKALOIDS. One small study investigated the use of vinblastine as a combination of rituximab, cyclophosphamide, vincreistine, and prednisone in 16 chronic ITP patients who had relapsed or had not responded to rituximab therapy. The treatment was not well tolerated, and there was no benefit observed with regard to response over the standard dose of rituximab (evidence level Ib).

Because of the neurotoxicity of vinca alkaloids, they are never used as a chronic form of therapy (supplemental Table 3).

**Subsequent therapy: surgical**

**Recommendations for surgical therapy for persistent and chronic ITP in adults**

1. Splenectomy is associated with long-term treatment-free remissions. It is recommended to wait ≥12 to 24 months from diagnosis before performing splenectomy because of the chance of remission or stabilization of a platelet count at a hemostatic level (Grade C recommendation).

2. When available, indium-labeled autologous platelet scanning may be useful prior to splenectomy to confirm that the spleen is the main site of platelet sequestration (Grade B recommendation).

3. Laparoscopic splenectomy is as effective as open splenectomy in terms of response and is more comfortable for the patient (Grade B recommendation).

4. Postoperative thromboprophylaxis should be considered in patients undergoing splenectomy as long as the platelet count is ≥30 to 50 × 10^9/L (Grade C recommendation).

5. Splenectomy should be performed by a surgeon experienced in identifying accessory splenic tissue, which is common and should be removed (Grade C recommendation).

6. Appropriate vaccination against *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* must be provided ≥2 weeks before splenectomy and maintained according to national guidelines; recent treatment (within 6 months) with rituximab may impair vaccination efficacy.

7. Patients should be informed of the long-term risks of splenectomy (increased rates of thrombosis, infection, and cancer) and educated to follow advice aimed at mitigating these complications (Grade C recommendation).

8. Antibiotic prophylaxis should be given as per national guidelines (Grade C recommendation).

**Splenectomy.** Splenectomy was previously considered a second-line surgical therapy. Here, “Subsequent therapy: surgical” covers the efficacy, patient acceptability, procedure timing, and adverse effects of splenectomy (supplemental Table 3).

**WHEN TO PERFORM SPLENECTOMY.** It is recommended to wait ≥12 to 24 months from diagnosis before performing splenectomy because of the chance of remission or stabilization. One single-center study reported that very low platelet counts (<10 × 10^9/L) should not necessarily be a contraindication for laparoscopic splenectomy in patients with ITP. Ideally, platelet counts should be increased if possible to ≥50 × 10^9/L prior to the procedure to reduce postsurgical complications (evidence level IV). Steroids, IV Ig, TPO-RAs, or other effective therapy may be used to increase platelet counts prior to splenectomy.

**RESPONSE RATES.** Initial overall response rates of up to 90% have been reported in studies of splenectomy in patients with ITP, but these data may be exaggerated by spontaneous remission. Response has been maintained for 10 years in 78% of patients, and a 20-year relapse-free survival of 67% has also been reported. However, up to 19% of patients have no formal response to splenectomy; nevertheless, some attain a hemostatic platelet count (evidence level IIb).

Two studies have compared splenectomy with rituximab; the other reported significantly higher rates of response and complete response at 3 and 12 months with splenectomy vs rituximab in corticosteroid-refractory patients, the reported significantly higher rates of response and complete response at 3 and 12 months with splenectomy vs rituximab in patients with persistent/chronic ITP (evidence level IIb).

**PREDICTORS OF SUCCESS.** Retrospective analyses have reported no significant impact of baseline characteristics (including age, sex, and interval from diagnosis to splenectomy) on response to splenectomy (evidence level IIb) or response to splenectomy (evidence level IIb). However, age ≥60 years is associated with significantly higher rates of relapse and postoperative complications (evidence level IIb).

Indium-labeled autologous platelet scanning may be able to predict response to splenectomy but is not widely available.

**OPEN VS LAPAROSCOPIC SPLENECTOMY.** Laparoscopic splenectomy is associated with significantly shorter hospitalization, less intraoperative blood loss, and quicker resumption of oral diet compared with open splenectomy (evidence levels IIb-III) in adults. Postoperative complication rates are reported to be nonsignificantly lower with laparoscopic vs open splenectomy, and response rates are similar with the 2 methods.

**COMPLICATIONS.** Postsplenectomy, patients may have a higher risk for thromboembolism and infections (eg, pneumonia, meningitis, and septicemia). These events may be easily resolved or life-threatening; they may occur within a few days of surgery or after longer follow-up. Age ≥60 years has been reported to be associated with significantly higher complication rates. A retrospective observational study reported an association between preoperative use of TPO-RAs and reduced complications (evidence level IIb). In another study, computed tomography scans performed 3 to 7 days postsplenectomy showed portal vein or splenic vein clots in 22 of 30 ITP patients; repeat scans done ~42 days later showed resolution of 80%.

Due to the risk of bleeding, patients with ITP may be administered prophylactic platelet transfusions. However, a retrospective single-center study of splenectomy in patients with low platelet counts...
reported no significant difference in volume of blood loss or excessive bleeding incidence between patients with platelet counts <10 × 10^9/L receiving a platelet transfusion and those with counts ≥10 × 10^9/L (evidence level IIb).\(^{191}\)

**PREVENTION OF INFECTION AFTER SPLENECTOMY.** Patients who have undergone splenectomy are at a higher risk for severe infection, even 10 years after the procedure.\(^ {208}\) Infection risk may be reduced, although not completely,\(^ {193}\) through antibiotic prophylaxis and vaccination. Appropriate vaccination against *S pneumoniae, N meningitidis*, and *H influenzae* must be provided, preferably before splenectomy. Vaccination should be performed ≥6 months before treatment with rituximab if possible.\(^ {175}\) The latest national guidelines (eg, Centers for Disease Control and Prevention, https://www.cdc.gov/vaccines/schedules/index.html) on vaccination presplenectomy and on antibiotic prophylaxis postsplenectomy should be followed.

**Partial splenic embolization.** Partial splenic embolization could, if necessary, be performed as an alternative to splenectomy. A retrospective single-center analysis of 91 ITP patients reported an overall response rate of 84% and a 10-year failure-free survival of 52%, concluding that partial splenic embolization generates long-term durable responses (evidence level III).\(^ {208}\) The most common AEs included grade 1 nausea, fever, and abdominal pain.\(^ {208}\) This single-center experience needs confirmation.

**Treatment options for adults failing multiple therapies**

| Recommendations for adults failing multiple therapies |
|-------------------------------------------------------|
| 1. For patients failing multiple prior therapies, it is important to: |
| a. Reconsider the diagnosis |
| b. Perform bone marrow examination if not already done |
| c. Reassess the need for treatment (consider platelet count/bleeding risk) |
| d. Consider referral to an ITP treatment center |
| e. Reassess the adequacy of prior therapies (eg, was the full dose of TPO-RA explored? Did the addition of a small dose of corticosteroid improve response?) |
| f. Assess the risks and benefits of further treatment |
| g. Reassess the possibility of splenectomy if not already performed |
| h. Consider other medical therapies if not already attempted (eg, MMF, fostamatinib, rituximab, azathioprine, dapson, danazol) |
| i. Consider enrollment in a clinical trial |
| 2. In patients who relapse >1 year after responding to splenectomy, a search for accessory spleen should be conducted and, if found, resected (Grade C recommendation). |
| 3. Switching from 1 TPO-RA to another and sequential therapy have been shown to have a positive effect on response and AEs. |
| 4. Other therapies that have been used as last resorts include combination chemotherapy, alemtuzumab, and hematopoietic stem cell transplantation (HSCT). The side effects of these treatment options may be severe, and the data supporting their use are limited (Grade B recommendation; evidence level III). |

Approximately 20% of patients do not attain a hemostatic platelet count after splenectomy\(^ {37,192-197}\) or fail to respond to initial or subsequent medical approaches; an additional 20% to 30% of splenectomy responders eventually relapse (evidence level IIb).\(^ {37,195}\) However some of these patients may nevertheless maintain a hemostatically effective platelet count without necessitating further treatment. The term “refractory” was proposed by an IWG for patients remaining at risk for significant bleeding after failing previous treatments, including splenectomy.\(^ {48}\) But the authors eschew the use of this term because many patients will eventually attain a hemostatically effective platelet count without splenectomy. Some patients with ITP have disease that is less responsive to multiple forms of therapy or have rejected splenectomy. These patients may be able to tolerate severe thrombocytopenia (ie, platelet counts as low as 10 × 10^9/L) relatively well with near-normal HRQoL or choose to live with low platelet counts instead of undergoing treatments that may be toxic (supplemental Table 4). However, some patients have consistent and substantial deficits on HRQoL, bleeding, and increased risk for death. In this situation, the risk of further therapy must be discussed with the patient and compared with the benefit of that therapy. In addition, other potential etiologies for thrombocytopenia should be exhaustively explored. If not recently performed, a bone marrow examination should be done.

Therefore, this section will focus on those who have failed multiple prior therapies (at least TPO-RA and rituximab) and usually splenectomy, as well as those who have failed multiple prior therapies (TPO-RA and rituximab) but who are ineligible for or refuse splenectomy. For those failing multiple therapies and who still require treatment, to date, no treatment algorithm has been evaluated in RCTs. Some patients failing to respond to 1 TPO-RA may respond if switched to another TPO-RA (evidence levels IIb, III).\(^ {138,148,210,211}\) If not already done, splenectomy can also be reconsidered, as can searching for an accessory spleen.\(^ {212}\) In patients failing 1 medical therapy, changing to another medical treatment may be successful. Rare patients may benefit from HSCT.

**Switching TPO-RAs.** New data have shown that switching from 1 TPO-RA to another, as well as sequential therapy, has a positive effect on response and on tolerability (evidence levels IIb, III).\(^ {138,148,210}\) Switching was shown to be effective in 50% to 80% of patients, resulting in eradication of platelet fluctuation in 54% of patients and resolution of AEs in all (evidence level IIb).\(^ {138}\) Another study showed that switching from romiplostim to eltrombopag led to 100% response rates, but switching from eltrombopag to romiplostim led to 66% response rates, when patients switched as a result of inefficacy of the first treatment. When switching was due to side effects or for preference, 100% of patients responded (evidence level III).\(^ {211}\) One study on sequential treatment revealed that sequential romiplostim and eltrombopag led to responses of 80%, and median time to relapse was 5.5 months.\(^ {211}\)

The panel rejected using both TPO-RAs simultaneously because of excessive costs.

**Accessory splenectomy.** In patients who relapse following an initial response to splenectomy, radiographic assessment for accessory spleen should be considered.\(^ {212}\) One study of 14 patients with ITP resistant to treatment found a response rate to
accessory splenectomy of 50% at 4 weeks in adult and pediatric patients. A positive outcome was correlated with being female, having a favorable response to prednisone at first exposure, and absence of Howell-Jolly bodies prior to intervention. Although the study suggests that laparoscopic accessory splenectomy is a treatment option for patients with ITP that is resistant to splenectomy, the added risk of morbidity and the difficulty of finding an accessory spleen in a previous surgical field must be weighed against the likely effectiveness (50%-60%) of the procedure (evidence level IIb).  

**Combination therapy.** Two studies assessed combination therapy. Azathioprine + MMF + cyclosporine was well tolerated and resulted in response rates of 73.7% maintained for a median of 24 months in patients failing multiple prior treatments (evidence level III). Three cycles of rituximab + cyclophosphamide, vincristine, and prednisone given every 3 weeks was not well tolerated as an intensified rituximab regimen when given to patients relapsing after a standard rituximab dose or to nonresponders (evidence level Ib), and it showed no benefit over standard-dose rituximab (evidence level Ib).  

**Alemtuzumab.** As a single agent, alemtuzumab has rarely shown effect in ITP. However, low-dose rituximab (100 mg weekly for 4 weeks) in combination with alemtuzumab (10 mg subcutaneously on days 1-3) has produced responses in all 11 ITP patients that lasted >80 weeks in 60% (evidence level III). However, the panel cannot recommend this approach because of the perceived side effects of the dual immunosuppression. Overall, however, lower-dose rituximab may be associated with shorter responses and earlier relapses. For details on alemtuzumab alone see supplemental Table 4.  

**HSCT.** HSCT is warranted only in patients with severe chronic nonresponsive ITP with bleeding complications unresponsive to other modalities; it should be used only in very limited cases. For details see supplemental Table 4; no new data were found.  

**Clinical trials.** There are a number of promising new therapies for ITP, including Bruton’s tyrosine kinase inhibitors, neonatal Fc receptor inhibitors, proteasome inhibitors, and complement inhibitors.  

**Supportive care**  
ANTIFIBRINOLYTICS. See “Emergency treatment.”  
INHIBITION OF MENSTRUAL BLEEDING. To decrease menstrual bleeding frequency and amount, progesterone-containing intrauterine devices and oral contraceptives can be used (evidence level Ib); no new data were found.  

**ITP during pregnancy**  

**Presentation of thrombocytopenia during pregnancy**  
ITP is estimated to occur in 0.83 of 10,000 pregnant women and has a variable course, usually worsening as pregnancy progresses. Diagnosis is similar to the nonpregnant patient but the differential diagnosis includes pregnancy-specific conditions, such as gestational thrombocytopenia and pregnancy-induced hypertensive disorders. Both of these develop in late gestation, with ITP being the most common cause of thrombocytopenia early in pregnancy.  

**Recommendations for investigation of suspected ITP in pregnancy**  
1. Patients with a history suggestive of ITP or those with a platelet count $<80 \times 10^9$ should be investigated for possible ITP (Grade C recommendation).  
2. As in nonpregnant patients, the diagnosis of ITP is one of exclusion using the patient’s history, physical examination, blood counts, and blood smear examination (Grade C recommendation).  
3. Laboratory evaluation is similar to the nonpregnant patient, but special consideration should be given to rule out hypertensive, microangiopathic, coagulopathic, and hepatic disorders associated with pregnancy. Recommended tests should be based on the clinical features and may include review of the blood smear, reticulocyte count, coagulation screen, liver function, thyroid function, ANAs, and APLAs (Grade C recommendation).  
4. Bone marrow examination is not recommended unless there are atypical features (Grade C recommendation).  
5. Anti-platelet antibody testing does not predict the course of maternal or neonatal thrombocytopenia or distinguish ITP from gestational thrombocytopenia and is not recommended (Grade C recommendation).  
6. Testing of TPO levels is not recommended (Grade C recommendation).  

**Special considerations in the differential diagnosis of thrombocytopenia in pregnancy.** The mean platelet count in pregnant women is lower than in nonpregnant women. A decrease of ~10% in the second half of pregnancy is caused by a combination of hemodilution, increased platelet activation and clearance, and platelet sequestration in the placenta. Approximately 10% of women with otherwise uncomplicated pregnancies have gestational thrombocytopenia with a platelet count $<150 \times 10^9$ at the time of delivery. Platelet counts $<100 \times 10^9$ are much less common (1.0%) and counts $<80 \times 10^9$ are rare (0.1%) in patients without other etiologies. As in nonpregnant adults, ITP is a disorder of exclusion. Examination of the peripheral blood smear is required to rule out the presence of red blood cell fragmentation seen with microangiopathic hemolysis and preeclampsia. Coagulation and liver abnormalities may suggest an alternative diagnosis, such as hemolysis, elevated liver enzymes, and low platelet count syndrome, infection, or DIC. Additional laboratory testing will be guided by a patient history of thrombocytopenia, bleeding, thrombosis, or pregnancy loss or other laboratory or clinical findings. Unlike ITP in nonpregnant patients, TPO levels may be elevated, but testing is not routinely recommended. Bone marrow examination is very rarely required for the diagnosis, and testing for platelet autoantibodies is not helpful and may be misleading. See Table 7 for testing recommendations.  

ITP developing late in gestation may be difficult to distinguish from other causes of thrombocytopenia, but the presenting platelet count is often lower than for gestational thrombocytopenia or hypertensive disorders ($P = .000$ and $P < .05$, respectively) (evidence level III). The latter occur during late gestation and are not associated with neonatal thrombocytopenia.
Recommendations for the treatment of maternal ITP

1. Counseling for women with ITP wishing to become pregnant (Grade C recommendation).
2. A platelet count between 20 and \(30 \times 10^9/L\) in a nonbleeding patient is safe for most of pregnancy. A platelet count \(>50 \times 10^9/L\) (see separate anesthesia recommendation below) is preferred for delivery (Grade C recommendation).
3. Initial treatment is with oral steroids or IVlg (Grade C recommendation).
4. IV anti-D in Rh(D)-positive nonsplenectomized women appears to be well tolerated and effective based on results from a small pilot study\(^{225}\) (Grade B recommendation, evidence level IIb); however, this may potentially cause maternal or fetal hemolysis.
5. IVlg can provide a rapid, but often very transient, increase in platelet count and can be used to urgently increase platelet counts during bleeding or for delivery (Grade B recommendation).
6. Combining therapies (prednisone with IVlg and/or IV anti-D) may elicit a response in patients refractory to single agents alone (Grade C recommendation). High-dose methylprednisolone, in combination with IVlg and/or azathioprine, is suggested for patients refractory to oral corticosteroids or IVlg alone (Grade C recommendation).
7. Rituximab can be considered in pregnancy for very severe cases, but perinatal and neonatal immunosuppression and subsequent infection are potential complications and require monitoring (Grade C recommendation).
8. TPO-RAs may be considered in late pregnancy when other treatments have failed, but published information is limited (Grade C recommendation).
9. In the rare instances when splenectomy is required, it should be performed in the second trimester (evidence level III; Grade C recommendation).
10. Vinca alkaloids, danazol, and immunosuppressive drugs not listed in these recommendations should be avoided in pregnancy (Grade C recommendation).

Known toxicity and limited experience in pregnancy with many of the medications commonly used in ITP limit treatment options. In addition, the mother’s platelet count does not predict fetal platelet count, and therapy of the mother is not known to affect neonatal outcome.\(^{223,226,227}\)

Initial treatment

ORAL CORTICOSTEROIDS. Low-dose corticosteroids are first-line therapy, although 1 retrospective study of 88 patients suggests that they may be less effective in pregnancy, with <40% of patients achieving an increase in platelet count with these treatments.\(^{226}\)

Prednisone, 20 mg/d, is recommended initially and then adjusted to the minimum dose necessary, because corticosteroids can cause hypertension, hyperglycemia, osteoporosis, weight gain, and psychosis. After delivery, the platelet count should be monitored, and corticosteroids should be tapered slowly to avoid a rapid decrease in platelet count and to ensure that the mother’s mental state is not affected (evidence level IV).

IVlg. IVlg may increase the platelet count faster than corticosteroids (2 ± 1 days vs 16 ± 19 days [mean ± standard deviation], respectively) (evidence level IIb).\(^{226}\) Infusions are generally well tolerated, although they present a significant volume and protein load. Retrospective studies have shown comparable efficacy of corticosteroids and IVlg (\(P = .465\)) (evidence level III)\(^{223}\) as well as similar neonatal outcomes (evidence level IIb).\(^{226}\) Patients may occasionally require IVlg to maintain safe platelet counts throughout pregnancy or especially in preparation for delivery when a rapid platelet increase is required (evidence level IV).

IV anti-D. If available, IV anti-D in Rh(D)-positive nonsplenectomized women appears to be well tolerated (by mother and fetus) and is effective in the second and third trimesters based on results from a small pilot study (evidence level III).\(^{225}\) Monitoring is required for neonatal jaundice, anemia, and DAT positivity after delivery. Anti-D is not available in Europe.

Management of pregnant patients with ITP failing initial treatment

COMBINING INITIAL THERAPY. Patients refractory to initial single therapy or whose platelet counts fall despite continued therapy may respond to combining initial therapy agents or adding other agents. For patients refractory to oral corticosteroids, high-dose methylprednisolone in combination with IVlg or azathioprine is suggested. Cyclosporine A and azathioprine have been safely used in pregnant patients with orthotopic organ transplants.\(^{86,228}\) They may be effective in patients with ITP refractory to other therapies, but it could take weeks to increase the platelet count. There is increasing experience with rituximab before and during pregnancy; potential complications include perinatal and neonatal immunosuppression and subsequent infection.\(^{205}\) Other immunosuppressive agents, including vinca alkaloids and MMF, have been associated with teratogenicity and should not be used.\(^{229,230}\)

TPO-RAS AND RHTPO. TPO-RAs may be considered in exceptional circumstances, ideally only in the third trimester near delivery, although tolerability and toxic effects on the fetus have not been rigorously evaluated. An unpublished safety database (Amgen,
Table 7. Testing recommendations in suspected thrombocytopenia in pregnancy

| Tests                        | Notes                                                                 | Notes                                                                 |
|------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Recommended for all patients |                                                                       |                                                                        |
| CBC and peripheral blood smear review | Macrothrombocytopenia                                                   |                                                                        |
| Check for other inherited thrombocytopenias |                                                                       |                                                                        |
| Depending on family history and smear, consider genetic testing, platelet function testing, testing for type 2b von Willebrand disease and platelet-type von Willebrand disease |                                                                        |
| Schistocytes may suggest microangiopathy in hemolysis and hypertensive disorders |                                                                        |                                                                        |
| Reticulocyte count            | Elevated in cases of hemolysis and hypertensive disorders              |                                                                        |
| Coagulation screening         | PTT may be prolonged in patients with a history of thrombosis or pregnancy loss. Consider testing for APLAs, anticoagulant. |                                                                        |
| PT/PTT, fibrinogen            |                                                                        |                                                                        |
| Liver function                | Possibly viral infection, if abnormal                                   | Check for hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). |
| Thyroid function              |                                                                        |                                                                        |
| Viral serologies (HIV, HCV)   |                                                                        |                                                                        |
| Renal function                | HUS/TTP may manifest for the first time in pregnancy. Consider testing for ADAMTS-13, alternative complement pathway. Consider atypical HUS due to autoantibodies against complement components |                                                                        |
| To be considered              |                                                                        |                                                                        |
| Anti-nuclear antibody         |                                                                        |                                                                        |
| H pylori testing              | H pylori stool or antigen test should be performed in patients with history of thrombocytopenia prior to pregnancy |                                                                        |
| Ig levels                     | Quantitative Ig test should be performed in patients with a history of thrombosis or pregnancy loss |                                                                        |
| Not recommended               |                                                                        |                                                                        |
| Platelet autoantibody testing | Not predictive of neonatal platelet count                               |                                                                        |
| Bone marrow examination, peripheral blood flow cytometry |                                                                        |                                                                        |
| Fetal blood sampling          |                                                                        |                                                                        |
| TPO level                     | May be of value in the future                                          |                                                                        |

HUS, hemolytic-uremic syndrome; PT, prothrombin time; TTP, thrombotic thrombocytopenic purpura.

Thousand Oaks, CA) exists for >25 women treated with romiplostim during pregnancy without untoward effects. All available published data are from 11 available case reports, and all show a platelet response.119-121,141,231-237 Romiplostim and eltrombopag may cross the placenta and could cause potential harm to the fetus.119,120,227 In the 11 cases reviewed here, there were no safety concerns.119-121,141,231-237 TPO-RAAs are not recommended except in very serious cases; if used, romiplostim may be preferred given its fewer off-target effects (lack of hepatic toxicity and iron chelation) and limited safety database.

rhTPO is likely to cross the placenta and was effective in increasing the platelet count in 23 of 31 pregnant women who were unresponsive to steroids without untoward effects on the fetus.227 rhTPO is only available in China.

SPLENECTOMY. Splenectomy is required in very rare cases. It is best performed in the second trimester, by laparoscopy if possible and with vaccination according to national guidelines.

VENOUS THROMBOEMBOLISM. In addition to the known prothrombotic state of pregnancy, some women may have risk factors (eg, antiphospholipid antibody syndrome) requiring venous thromboembolism prophylaxis (evidence level IV). A platelet count $>$50 $\times$ 10^9/L is generally recommended for such patients receiving anticoagulation (evidence level IV).

**Preparation for delivery: obstetric analgesia and anesthesia**

**Recommendations for obstetric analgesia and anesthesia**

1. **At a platelet count $\geq 70 \times 10^9/L$, in the absence of other hemostatic abnormalities, regional axial anesthesia can be safely performed (Grade C recommendation).**

2. **NSAIDs should be avoided for postpartum or postoperative analgesia in women with platelet counts $<70 \times 10^9/L$ because of increased hemorrhagic risk (Grade C recommendation).**

3. **A platelet count $\geq 50 \times 10^9/L$ should be obtained for delivery (Grade C recommendation).**

4. **All women, despite having ITP, who are at an increased risk for thromboembolism should receive appropriate prophylaxis for venous thromboembolism (Grade C recommendation).**

5. **The mother with a rapidly falling platelet count should be observed more closely than those with low, but stable, levels (Grade B recommendation).**

The minimum platelet count required for delivery has not been defined, although a count $\geq 50 \times 10^9/L$ is generally recommended.
Discussion about regional anesthesia should include the obstetric anesthetist and take place before the expected delivery date so a plan is in place for increasing the platelet count if needed. A systematic review of 1524 thrombocytopenic parturients estimated the risk of epidural hematoma. More than 500 women with platelet counts of 70 to 100 × 10^9/L were included, almost 300 of whom underwent epidural blockade. Although no hematomas occurred, the estimated potential risk of epidural hematoma was 0.2%.\textsuperscript{238} Limited observations with a count <70 × 10^9/L are available, and the risk is poorly defined, but no cases requiring surgical decompression were observed. Risk of vascular damage likely decreases proportionately to needle size; consequently, spinal injection may be a safer option than epidural blockade in patients with increased bleeding risk or platelet counts <70 × 10^9/L. Evaluation before neuraxial anesthesia should include whether there is a history of bleeding, presence of bruising, or abnormal coagulation testing (including prothrombin time, activated PTT, and fibrinogen levels) that may increase the risk of bleeding. The role of thromboelas-tography or rotational thromboelastometry in assessing global hemostasis is unclear, and their use cannot be recommended. Although a platelet count ≥70 × 10^9/L is recommended for neuraxial anesthesia, this must be weighed against the risk of general anesthesia for the patient. The trend of the platelet count is important, as well as the absolute value. A mother with a falling count should be observed more closely than one with low, but stable, counts.

**Delivery: management of mother and infant**

### Recommendations for management of delivery and newborn infants

1. Cordocentesis and fetal scalp blood sampling should be avoided in the management of the fetus/neonate of a mother with ITP in pregnancy (Grade C recommendation).
2. Neonatal alloimmune thrombocytopenia should be excluded by parental testing if the neonate presents with severe thrombocytopenia (Grade C recommendation).
3. The mode of delivery should be determined by obstetric indications, not by anticipation of the neonatal platelet count (Grade B recommendation).
4. Procedures during labor that may be associated with increased hemorrhagic risk to the fetus should be avoided, specifically the use of fetal scalp electrodes, fetal blood sampling, ventouse delivery, and rotational forceps (Grade C recommendation).
5. Previous splenectomy has been associated with worsening of maternal ITP in pregnancy (evidence level III\textsuperscript{219} and a higher risk for neonatal thrombocytopenia (evidence levels IIb, III\textsuperscript{219}; Grade B recommendation).
6. A mother with a previous newborn, thrombocytopenic or not, is likely to have a second baby with a similar platelet count.

Optimal management of delivery is based on obstetric indications with avoidance of procedures that may induce bleeding. The very low risk of ICH in the fetus/neonate of the mother with ITP has not been shown to be lessened by Caesarean section, in part because it is so infrequent.

### Management of neonate

#### Recommendations for management of neonates born to women with ITP

1. Umbilical cord platelet count should be obtained at the time of delivery or as soon as possible (Grade C recommendation).
2. Repeat the platelet count as needed depending on platelet levels, trends in the count, and response to treatment (if any). If cord platelet count is <100 × 10^9/L, repeat the platelet count daily until stable (Grade C recommendation). The incidence of pseudothrombocytopenia is high in neonates because of the difficulties encountered in obtaining unclotted blood with blood draws (Grade C recommendation).
3. If platelet count is <50 × 10^9/L at birth, perform a cranial ultrasound. A magnetic resonance imaging for confirmation or clarification can be performed without anesthesia using the sleep and swaddle approach 30 to 60 minutes prior (Grade C recommendation).
4. In the case of ICH, give IVIg and limited steroids to maintain platelet count >100 × 10^9/L for 1 week if possible and >50 × 10^9/L for another week (Grade C recommendation). The use of platelet transfusion may increase neonatal risk.
5. If there is symptomatic bleeding or if platelet count is <30 × 10^9/L, with or without platelet transfusion, give IVIg (Grade C recommendation).
6. If severe thrombocytopenia continues for >1 week in a breast-fed infant, consider pausing breastfeeding for a few days to see whether platelet count increases (Grade C recommendation).
7. Women who had a splenectomy may have a thrombocytopenic newborn, even if their platelet count is normal (Grade C recommendation).
8. The only currently reliable predictor of whether a baby will be thrombocytopenic is if a previous sibling was thrombocytopenic (Grade B recommendation).

A platelet count from a postnatal cord sample is recommended and, if low, it should be repeated at 3 to 5 days of age, when the neonatal spleen has matured. The risk for ICH in newborns with platelet counts <30 × 10^9/L is estimated at <1%,\textsuperscript{239} but given the significant implications of such an event, IVIg should be given to increase the platelet count. Experience shows that, when the neonatal platelet count oscillates, this may reflect platelet clumping (pseudothrombocytopenia) as a result of difficulty obtaining blood from newborns. Splenectomized women, and especially mothers with previous thrombocytopenic newborns, are at greatest likelihood of having a thrombocytopenic newborn. Anti-platelet antibody in breast milk may contribute to persistence of neonatal thrombocytopenia.\textsuperscript{239}

### Counseling for women with ITP or who develop ITP in pregnancy

Women of child-bearing capacity with ITP should be counseled that ITP is almost never a contraindication for pregnancy. Ideally, management of women with ITP wishing to become pregnant should be performed jointly by an obstetrician...
experienced in high-risk pregnancies and a hematologist knowledgeable in ITP. In the authors’ experience, serious bleeding complications antepartum or postpartum are extremely rare (evidence level IV).

**ITP in children**

**Diagnostic approach in children with suspected ITP**

The diagnosis of ITP in children is one of exclusion. Children with newly diagnosed ITP, especially with atypical features, should be referred to a hematologist experienced in the assessment and treatment of children with ITP. Children and their parents will benefit from contacts, literature, and Web-based information available, especially from ITP support groups.

**Recommendations for initial investigation of suspected childhood ITP**

1. A complete history, physical examination, full blood count, and expert analysis of the peripheral blood smear should be performed and carefully evaluated at initial diagnosis (Grade C recommendation).
2. A DAT is recommended to exclude coexistent autoimmune hemolytic anemia, especially prior to therapy (Grade C recommendation).
3. Baseline Ig levels, to exclude coexisting immunodeficiency, is recommended prior to therapy (Grade C recommendation).
4. When the CBC shows isolated thrombocytopenia and no abnormal features beyond thrombocytopenia on examination of the blood smear and signs of bleeding are present on physical examination, a bone marrow aspiration/biopsy is not required in children, even prior to steroid therapy (Grade B recommendation).
5. Children with newly diagnosed ITP, especially with atypical features, should be referred to, or discussed with, a hematologist experienced in assessment and treatment of children with ITP (Grade C recommendation).
6. Bone marrow aspiration, biopsy, and cytogenetics should be performed if abnormal or potentially malignant cells are visualized on smear and carefully considered if there are other abnormalities of the hemoglobin and/or white cell count (with the exception of microcytic anemia) or if there is hepatosplenomegaly and/or adenopathy. In addition, failure to acutely respond to ITP therapy merits a bone marrow examination (Grade C recommendation).
7. Additional investigations are based on clinical assessment and may include a variety of testing, including molecular genetics, autoantibody screening, liver-spleen imaging, and other laboratory testing (Grade C recommendation).

See Table 3 for diagnostic tools for adults and children with suspected ITP.

**Differential diagnosis.** Although presentation of ITP in children is generally acute, less commonly, bruising and purpura may develop slowly over weeks or months, suggesting a chronic evolution. It is important to exclude other common disorders that may resemble ITP (Table 4).

If a decision is made to observe the child with presumed newly diagnosed ITP, even in typical cases, a CBC and blood smear should be repeated periodically to exclude the evolution of a serious bone marrow or other hematologic disorder until the diagnosis is clear or recovery has occurred.

Children with familial inherited thrombocytopenias are often misdiagnosed as having ITP. Inherited disorders should be suspected if thrombocytopenia has been present since early life, a positive family history for a similar disorder is elicited, characteristic features are present, or there is failure to respond to first-line treatment. If available, genetic panels for blood and bone marrow can be used to identify specific genetic alterations associated with the thrombocytopenia and may predict future risk of clonal disease evolution. Mean platelet volume may be used to differentiate ITP from inherited thrombocytopenia (evidence level IIb); increased mean platelet volume can be suspected on smear if there are many large platelets.

**SPECIAL DIAGNOSTIC CONSIDERATIONS IN CHILDREN.** Older children and those with slow evolution of disease (evidence level Ib-III) may be more likely to develop chronic disease. Other autoimmune diseases associated with thrombocytopenia, including SLE, CVID, autoimmune lymphoproliferative syndrome, and chronic viral infections, should be considered difficult, persistent, and chronic cases and in those with multiple autoimmune cytopenias (eg, Evans syndrome).

**BONE MARROW EVALUATION.** Bone marrow evaluation in children with newly diagnosed ITP is recommended only when abnormalities are present other than isolated thrombocytopenia in the blood count/smear, if systemic features (eg, bone pain) are apparent, or if the patient has an enlarged spleen not secondary to liver disease. Bone marrow evaluation (aspirate and biopsy) should be carefully considered in cases who respond minimally or not at all to first-line therapies to exclude bone marrow failure; a high mean cell volume, even without anemia, could indicate marrow failure. Genetic panels for inherited thrombocytopenia or congenital marrow failure should also be considered at the time of marrow evaluation.

**H PYLORI INFECTION.** The rate of *H pylori* positivity in children with ITP is reported to be 20% to 29%. There is conflicting evidence on the effect of *H pylori* eradication in positive children (evidence levels IIa and Ib). In certain children with ITP, eradication of *H pylori* may improve the platelet count; however, this is inconsistent and cannot be relied upon.

**Recommendations for subsequent investigation of children with persistent or chronic ITP**

1. Repeat history, physical examination, full blood count, and expert analysis of the peripheral blood smear should be performed to reassess diagnosis (Grade C recommendation).
2. Bone marrow aspiration, biopsy, and cytogenetics should be performed at 3 to 6 months if there has been no spontaneous platelet increase and no response to treatment (Grade C recommendation). NGS or targeted sequencing should be considered if available.
3. Bone marrow aspiration, biopsy, and cytogenetics should be performed earlier if there is no response to treatment within the expected timeframe (Grade C recommendation). NGS or targeted sequencing should be considered if available.

4. A bone marrow biopsy is not indicated prior to further therapy (eg, with TPO), unless the diagnosis is not certain (Grade C recommendation).

5. Additional evaluation could include testing for (Grade C recommendation):
   a. Lupus and other markers of autoimmune diseases that might require specific treatment (eg, test for APLAs, ANAs, anti-cardiolipin antibody, lupus anticoagulant, and serum lgs)
   b. Chronic infections (hepatitis, cytomegalovirus, HIV, and/or H pylori in at-risk populations or when there is no other explanation)
   c. Complex immunodeficiency diseases
   d. Genetic screening for inherited thrombocytopenia and bone marrow failure syndromes

6. In the setting of increasingly difficult-to-treat persistent or chronic ITP, consideration of bone marrow examination should be included in reevaluation of the diagnosis (Grade C recommendation).

EXAMINATION OF PATIENTS WITH PERSISTENT OR CHRONIC ITP. For patients diagnosed with ITP who have no improvement in platelet count after 3 to 6 months and still require treatment, several evaluations are recommended (see “Recommendations for subsequent investigation of children with persistent or chronic ITP”).

Management of ITP in childhood: general measures

From registry and cohort data, 0% to 4% of children with newly diagnosed ITP have severe (grade 4) bleeding requiring immediate intervention (evidence level III)\(^{245,250}\); bleeding that may require treatment is reported in 30% to 56% of newly diagnosed children (evidence level IIb-III)\(^{245,250,251}\). The incidence of ICH in children with ITP is ~0% to 1% (evidence level III)\(^{245,250,252-256}\) and predicting with confidence which children will develop an ICH is very imperfect. Risk factors for ICH include low platelet count,\(^{252}\) head trauma,\(^{252}\) signs of other bleeding (especially grade 3 and macroscopic hematuria), and possibly other less well-documented factors, including NSAIDs and arteriovenous malformation. Caution should be exercised in the management of children with ITP and coexisting vasculitis or coagulopathies, as may occur in the setting of other illnesses, especially with regard to inciting thrombosis.

Current consensus favors consideration of multiple factors when deciding to treat or not to treat children with ITP, including bleeding symptoms, the platelet count, recent trauma, existence of headache, recent medication use, and psychosocial and lifestyle issues, such as activity profiles and economic impacts. These considerations need to be discussed extensively with and explained to the patient and their family, whose wishes must be incorporated.

The management of children with persistent/chronic ITP is essentially the same as those with newly diagnosed ITP, with the exception that the longer the ITP lasts, the less likely it is to improve spontaneously and the more important the impact of the ITP on the patient’s and family’s quality of life becomes.

Clinical classification of newly diagnosed ITP in children

Recommendations for “clinical classification” of ITP in children

1. Clinical classification should be based on disease severity, including degree of bleeding, platelet count, comorbidities and their treatment (especially anticoagulation), and impact of ITP or its therapies on the patient’s and family’s HRQoL (evidence level IIb; Grade B recommendation).

2. Management should be considered based on the clinical classification (Grade C recommendation).

In children, the clinical features and symptoms of ITP are of greater impact in treatment decisions than just the platelet count. This leads to an effort to use a “clinical classification” of children based on degree of bleeding, platelet count, and other disease features. Bleeding scores exist for patients with ITP and should be routinely used for assessing severity of ITP (Table 8).\(^{94}\) These bleeding scores confirm that most children with ITP do not have serious bleeding problems, despite low platelet counts,\(^ {252,255,256}\) Of note, the severity of mucocutaneous bleeding does not consistently predict the risk for life-threatening bleeding (eg, ICH).

Expectant “watch-and-wait” policy

Recommendations for watch-and-wait policy based on clinical classification

1. At diagnosis, children and adolescents with ITP and mild or even moderate bleeding on a pediatric bleeding assessment tool (grade 1-3) may be managed expectantly with supportive advice and a 24-hour contact point, irrespective of platelet count (Grade B recommendation); those with grade 3 bleeding are more likely to require therapy because of the higher rates of serious bleeding requiring hospital admission and emergency treatment. All patients need regular reevaluation to monitor for worsening, including HRQoL and evolution to a serious bone marrow disorder or a secondary form of ITP (Grade C recommendation). The frequency of clinical and laboratory monitoring should be based on bleeding, HRQoL, trend in platelet counts, and impression of family reliability.

2. The same monitoring and 24-hour access are needed with persistent and chronic ITP, depending upon the factors listed above, but at less frequent intervals in a stable patient. Observation or watch and wait is less validated in patients with persistent and chronic ITP because it is based on the expectation of spontaneous future improvement (Grade C recommendation).

Bleeding grades are described in Table 8.
Most children with newly diagnosed ITP do not have significant bleeding symptoms or other risk factors and may be managed without treatment at the discretion of the hematologist and the patient’s family (evidence levels II-III). Recent observational registries report that 19% to 35%, and even up to 84%, of children with newly diagnosed ITP can be managed without ITP therapy and without increased rates of severe bleeding. Reasons to institute therapy are associated with increased bleeding severity and with risk factors for ICH. In a recent study, 7 of 42 children with, as well as 1 of 58 children without, grade 3 bleeding at diagnosis were hospitalized within 1 month because of grade 3/4 bleeding. There is a trend for increased serious bleeding with increased number of bleeding sites.

Children with ITP and their parents need to understand the risks of serious or life-threatening hemorrhage with or without treatment. They should also be aware that drug therapy is often effective but may have side effects and, thus, is usually reserved for children at higher risk for serious hemorrhage. The potential negative, as well as positive, impact of treatment on the HRQoL of children and their parents, despite platelet increase, should also be communicated (see “Quality of life of children with ITP”).

**Hospitalization.** For children with an established diagnosis of ITP, hospital admission should be reserved for those who have grade 3/4 bleeding. Problematic psychosocial circumstances of child and family (eg, family history of noncompliance, behavioral issues, residence remote from a health care facility) and the effect of the ITP on the child’s and family’s HRQoL should also be considered. Parents should be advised to watch for other signs of bleeding and be given a contact name and telephone number where a physician can be reached at all times.

**Management of ITP in children**

| Grade | Bleeding | Management approach |
|-------|----------|---------------------|
| Grade 1 (minor) | Minor bleeding, few petechiae (<100 total) and/or >5 small bruises (<3 cm in diameter), no mucosal bleeding | Consent for observation |
| Grade 2 (mild) | Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding | Consent for observation |
| Grade 3 (moderate) | Moderate bleeding, overt mucosal bleeding, troublesome lifestyle | Intervention to reach grade 1 or 2 |
| Grade 4 (severe) | Severe bleeding, mucosal bleeding leading to decrease in Hb > 2 g/dL or suspected internal hemorrhage | Intervention |

This bleeding scale is based on the one used in the previous consensus report, updated based on the authors’ opinion.

Hb, hemoglobin.

**Table 8. Updated bleeding scale for pediatric patients with ITP**

3. Any moderate (grade 3) bleeding requires hospital review and consideration for admission and therapy (Grade C recommendation).

4. Treatment should be administered and hospitalization should be strongly considered in the following cases (Grade C recommendation):
   a. Worsening bleeding or significant comorbidities
   b. Risk of ICH (eg, head trauma or unexplained headaches); patients at higher risk for ICH include those with a history of moderate or severe bleed in the preceding 28 days, recent administration (within 8 hours) of NSAIDs, and another clinically significant coagulopathy (eg, von Willebrand disease). In the case of head trauma, treatment should precede a head computed tomography scan.
   c. A change in behavior or mood consistent with significant depression or irritability
   d. Parents are anxious about bleeding and do not believe that they can control (young child) or restrict (older child) their child’s activity.
   e. Parents cannot be relied upon to bring the child back readily if there is an emergency (eg, they live too far away, they cannot afford to return, there are additional social concerns).
   f. Child has not spontaneously improved and must be overly restricted in activities.
   g. Child needs to take an anticoagulant or antiplatelet agent.
   h. Higher risk of bleeding due to another medical or psychological issue

Bleeding grades are described in Table 8.

Most children newly diagnosed with ITP do not require any therapy because the platelet count will often reach safe levels within a few days (see “Expectant watch-and-wait policy”). However, children and adolescents with moderate (grade 3) bleeding are at higher risk for subsequent grade 4 bleeding and should be considered for early intervention until bleeding has decreased. Children with grade 4 bleeding should be hospitalized and treated immediately (Table 8).

**Recommendations for when to start initial treatment in children newly diagnosed with ITP**

1. Most children can be managed with watchful waiting as described (see “Expectant watch-and-wait policy”); Grade C recommendation.

2. Any severe (grade 4) bleeding requires immediate hospital admission and treatment to increase platelet levels until bleeding has decreased (Grade C recommendation).

**Recommendations for initial treatment of children with ITP when required**

1. If there is moderate or severe bleeding, IVIg and anti-D can often increase the platelet count to hemostatic levels (>50 x 10^9/L) within 24 to 48 hours. IVIg is
effective when given as a single dose of 0.8 to 1.0 g/kg (Grade A recommendation, evidence level Ib). Anti-D has similar efficacy to IVlg when given as a single dose of 75 μg/kg and is rarely associated with severe hemolysis (Grade A recommendation, evidence level Ib). High-dose steroid premedication is recommended for IV anti-D and is useful for IVlg.

2. A second dose of IVlg or anti-D may be administered if there is a suboptimal initial response and/or ongoing bleeding (Grade C recommendation).

3. Prednisolone should be given at 4 mg/kg per day in 3 or 4 divided doses for 4 days with no taper, with a maximum daily dose of 200 mg or at 1 to 2 mg/kg, with an 80-mg maximum daily dose, even in patients weighing >80 kg, for 1 to 2 weeks (Grade C recommendation).

4. If a response is seen (eg, platelets > 50 × 10^9/L), the prednisolone should be tapered, aiming to stop it by 3 weeks, even if the platelet count drops during the taper (Grade C recommendation).

5. If there is no response to the initial dose within 2 weeks, the prednisolone should be tapered rapidly over 1 week and stopped (Grade C recommendation).

6. In general, corticosteroids are used for grade 1 or 2 bleeding (Table 8) or for patients not responsive to IVlg (Grade C recommendation).

7. Corticosteroids are relatively contraindicated in the presence of severe infection or recent varicella contact (Grade C recommendation).

IV anti-D can be used if the patient is Rh positive, not splenectomized, does not have a positive direct Coombs test (DAT), and has hemoglobin ≥ 9 g/dL.

A retrospective comparison of methylprednisolone and dexamethasone as initial treatment in children with ITP reported similarly high (96.5%) response rates and minor AEs with both regimens (evidence level Ib).257

The third study reported on the use of high-dose dexamethasone in patients, including children, with acute or chronic ITP. Results were not split by age, but the treatment led to a 69% response rate; 7 of 8 responding patients with chronic ITP later relapsed (evidence level III).67 However, treatment was reported as well tolerated.

IVlg. The most common treatment schedule for IVlg in children with newly diagnosed ITP is 0.8 to 1 g/kg in a single dose,79,84,256,258-260 but some studies continue to use 0.4 g/kg per day over 5 days.244,261 It is often combined with steroids, antihistamines, and paracetamol to reduce side effects, especially headaches. Treatment is usually discontinued once a safe platelet count is reached, although it can be repeated as-if needed. In severe bleeding, a second dose of IVlg (0.8 to 1 g/kg) is often given if there has been no initial response to the initial dose.

Increased platelet count with IVlg has been reported in >80% of children with ITP (evidence level Ib-Iib).79,256,260 Common AEs include headache, nausea/vomiting, and fever/chills.79,256,259,261

As described above, 4 studies have compared IVlg with anti-D in children newly diagnosed with ITP; 3 studies reported no significant difference, and 1 study reported improved efficacy with IVlg (evidence level Ib-Iib).244,258,259,261

The phase 3 TKI trial compared single-dose IVlg (0.8 g/kg) with observation in children with newly diagnosed ITP, platelet count > 20 × 10^9/L, and grade 1-3 bleeding (evidence level Ib).256 Overall and complete response rates were significantly higher with IVlg vs observation at 1 week and 1 month, at 3 months only the complete response rate was significantly higher, and at 6 and 12 months there was no significant difference in either measure. The rate of chronic ITP development did not differ significantly between the 2 groups (~10% in each group).

IV anti-D. IV anti-D can be given to Rh(D)-positive children as a short infusion, and it is usually effective in transiently increasing platelet counts.90,244,258,259,261,262

Four studies since 2010 have evaluated the treatment efficacy of anti-D in newly diagnosed children with ITP and compared with IVlg, methylprednisolone (lo)ne, or both.244,258,259,261 Three studies reported no significant difference between single-dose anti-D (50 or 75 μg/kg) and IVlg (single-dose 0.8-1 g/kg or 5 × 0.4 g/kg per day) in children newly diagnosed with ITP (evidence level Ib-Ilb); 1 study also reported no difference compared with methylprednisolone (lo)ne (2 mg/kg per day) (evidence level Ib).244,258,259 One study reported higher efficacy with IVlg vs anti-D (50 μg/kg) in newly diagnosed treatment-naive acute ITP patients, although a higher dose of IVlg was used (2 g/kg total dose) (evidence level Iib).261 Subcutaneous anti-D has also led to platelet count doubling in 74% of children with acute or chronic ITP262 but it may induce a slower platelet increase than the IV formulation.

The most common adverse drug reactions observed in trials of children with ITP were headache, fever, chills, and injection.90 Anti-D is not available in Europe.
Emergency treatment in children

Recommendations for emergency treatment in children at any stage of their ITP

1. Combination therapy, including platelet transfusions, IV corticosteroids, and IVIg, with or without anti-D, is recommended. Platelet transfusions should be administered as a bolus, followed by continuous infusion in combination with IV high-dose steroids (eg, IV methylprednisolone, 30 mg/kg per day). IVIg (0.8-1.0 g/kg per day, with or without single-dose IV anti-D (75 µg/kg), should be given for ICH or other life-threatening or serious bleeding. A second dose of IVIg and IV steroids may be required if a platelet response is not seen within 24 hours of the initial dose (Grade C recommendation).

2. IVIg, steroids, and IV anti-D (if available) can be used to attempt to ensure the most likely and fastest platelet increase. Antifibrinolytics may be given if bleeding continues despite therapy (Grade C recommendation).

3. If there is an ICH, emergency splenectomy and/or neurosurgical control of bleeding should be considered in conjunction with emergency platelet-raising therapy, but medical treatment should never be delayed because of surgical or radiologic intervention if at all possible (Grade C recommendation).

4. TPO-RAs should be considered; they may aid the acute response in patients and prevent a decrease in platelet count if initial response to emergency therapy is lost (Grade C recommendation).

In organ- or life-threatening bleeding, a two- to threefold higher dose of platelets should be infused, together with IV high-dose corticosteroids, IVIg, and/or IV anti-D, and possibly vincristine. The goal is to increase the platelet count as immediately as possible to minimize or eliminate severe bleeding and continue with platelet count maintenance until bleeding has stopped and the risk of rebleeding has resolved. The risk of bleeding following ICH may necessitate long-term treatment. There is no role for emergency splenectomy unless patients have failed multiple other treatments. Studies have only supported the use of recombinant factor VIIa in patients with massive bleeding after trauma.263

Treatment options for children with persistent or chronic ITP

Recommendations for treatment of persistent or chronic ITP in children

1. Most children can be managed with watchful waiting, as described (see “Expectant watch-and-wait policy”; Grade C recommendation).

2. Rescue therapy with corticosteroids, IVIg, and/or IV anti-D can be used in children on watchful monitoring to treat acute bleeding episodes if/when they occur (Grade C recommendation).

3. Children who are having frequent or severe bleeding episodes or impaired HRQoL (including reduction in important activities) require referral to a hematologist experienced in treating pediatric ITP for further treatment (Grade C recommendation).

4. Multiple pediatric studies support the use of TPO-RAs in children with persistent/chronic ITP, demonstrating good response and reduction in bleeding frequency with an absence of side effects in the majority of patients (evidence level Ib; Grade A recommendation).

5. If there is no response to 1 TPO-RA or there is a response that is lost, switch to an alternative TPO-RA and/or consider combining with MMF or another immunosuppressant (Grade C recommendation).

6. In those who fail TPO-RAs, especially adolescent females, rituximab and dexamethasone should be considered (evidence level III; Grade C recommendation).

Studies have indicated that older age,5,245,246 higher platelet counts,5,245,246 and absence of preceding infection5,246 are risk factors for chronic ITP (evidence levels Ib, III). Less established risk factors for chronicity include female sex245 and decrease in Ig (evidence level III).246 A recent registry analysis found no association between platelet count at diagnosis and ITP remission at 12 or 24 months.254 Spontaneous remission may occur at any time, even >3 years from diagnosis.264

Many children stabilize with an adequate platelet count (>20-30 × 10^9/L), have no symptoms unless injured, and do not benefit from restrictions in their activity.264 There may be ongoing vulnerability to excessive bleeding following trauma; it is advisable for the family to carry a card or letter or for the child to wear a bracelet with details of the disorder and contact information in case of emergency.

The role of puberty in this process remains uncertain. The onset of menstruation may be problematic and can be managed with antifibrinolytic agents and/or hormonal medication (see “ITP in adults” > “Emergency treatment”). Adolescents, in particular, may become very conscious of their appearance, in addition to other HRQoL issues, and need sympathetic support.

Treatment of children with persistent/chronic ITP consists primarily of TPO-RAs, rituximab, and MMF (supplemental Table 6).

Dexamethasone, high-dose methylprednisolone, IVIg/anti-D. There are few new data on these treatments in this population. For further details, see “Initial treatment options to increase platelet counts in children.”

TPO-RAs. Eltrombopag and romiplostim have been studied extensively in children, leading to FDA and European Medicines Agency licenses in children ≥1 year old with ITP for >6 months’ duration with insufficient response to corticosteroids, Igs, or splenectomy.120,121 In general, TPO-RAs should be used as preferred treatment in patients with ITP in whom alleviating the thrombocytopenia is likely to provide a clear clinical benefit, including reducing the risk of bleeding and/or improving the HRQoL.120,121 The lowest dose required to achieve and maintain a platelet count ≥50 × 10^9/L should be used for eltrombopag and romiplostim.120,121

If there is no response to 1 TPO-RA or there is a response that is lost and a TPO-RA is the best option for treatment, switch to
the alternative TPO-RA and/or consider combining it with MMF or another immunosuppressant (evidence level IV).

If a TPO-RA is initiated and effective, optimal duration of treatment is unknown. Consensus recommendation is to consider tapering the dose after 6 to 12 months of a stable response with a platelet count \(> 50 \times 10^9/L\) to determine whether it can be discontinued. Tapering can be tried again if it fails initially. Switching to another treatment, such as rituximab, immunosuppressants, or splenectomy, requires extensive discussion with the patient and/or family.

A retrospective study of TPO-RA in children with ITP (primary/secondary and newly diagnosed/chronic) reported a stable response rate of 40% and no significant difference in response pattern between romiplostim and eltrombopag (evidence level IIb).\(^{265}\)

Thrombocytosis was reported in more patients treated with eltrombopag than romiplostim (7 vs 2). TPO-RA treatment was discontinued in 54% of patients, with treatment being weaned in 32% and abruptly discontinued in 66%.\(^{265}\)

**Eltrombopag.** The dosing of eltrombopag depends upon the age of the patient (lower dose for age 1-5 years), presence of hepatic impairment (reduced dose with impairment), or East Asian ancestry (reduced dose).\(^{121,141}\) The dose should be adjusted according to platelet count, up to a maximum of 75 mg/d. See the prescribing information for full details.\(^{121,141}\)

The PETIT and PETIT2 studies of eltrombopag in children with chronic ITP reported a platelet count \(\geq 50 \times 10^9/L\) at least once in \(\approx 80\%\) of patients (evidence level Iib)\(^{266,267}\); in PETIT2, 40% of patients had a platelet count \(\geq 50 \times 10^9/L\) for \(\geq 6\) weeks without rescue.\(^{267}\) No World Health Organization grade 3 or 4 bleeding in patients on eltrombopag was reported in either trial.\(^{266,267}\) In the PETIT trial, 30% of children received the maximum dose of eltrombopag (75 mg/d); 89% of patients required \(\geq 1\) dose modification.\(^{266}\) Median time to response was 12 to 20 days, depending on the age of the patients.\(^{266}\)

There are few data on the administration of eltrombopag for \(> 1\) year in children.

**Romiplostim.** In children, the recommended initial dose is 1 \(\mu\)g/kg per week, administered subcutaneously; the dose can be adjusted depending on platelet count (see prescribing information for full details).\(^{119,120,121}\) A 24-week phase 3 study reported a median average dose of 3.9 \(\mu\)g/kg (interquartile range, 2.4-7.3) and a median most frequent dose during the final 8 weeks of 5.5 \(\mu\)g/kg (interquartile range, 3-10).\(^{268}\) In the absence of thrombotic risk, the authors use an initial dose of 3 \(\mu\)g/kg per week.

Studies of romiplostim in children with ITP (newly diagnosed and chronic) have reported overall response rates of 71% to 88%,\(^{268,270}\) and a median time to response of 4 to 5 weeks (evidence levels Ib-III).\(^{268,270}\) A study of long-term romiplostim treatment in children found AEs and platelet responses similar to those seen in adult patients and maintenance of effect over 4 years.\(^{271}\) However, another study with 24 weeks of romiplostim treatment reported no sustained response (platelet count \(\geq 50 \times 10^9/L\) for \(\geq 6\) months with no ITP medication) following romiplostim discontinuation (evidence level Ib).\(^{268}\)

**RITUXIMAB.** Rituximab is not approved for the treatment of ITP.\(^{175,176}\) However, studies report that it may induce responses in children with chronic ITP. Overall response rates to rituximab in this population are reported at 23% to 69% (evidence levels Iib-III).\(^{272-274}\) Relapse rates vary from 14% to 42% of responding patients, within \(\sim 1\) year (evidence levels Iib-III).\(^{161,273-275}\) In 1 study, 66 children with ITP were treated with rituximab; 57% had a response, but by 5 years only 26% maintained that response.\(^{161}\) These results are identical to those in adults, with the exception that 2 years after treatment, no children, but some adults, relapsed.

One study combined rituximab with dexamethasone and demonstrated an initial response rate of 45% and a relapse rate of 40% after 60 months (evidence level III).\(^{276}\) In adolescent female patients with ITP duration < 24 months, 47% maintained long-term remission without further therapy.\(^{276}\)

The studies of rituximab in children with ITP report that the treatment is generally well tolerated, with low levels of uralicarial rash, headache, chills, fever, and abnormal Ig levels. No cases of long-term toxicity due to B-cell depletion have been reported.\(^{161,273,274}\)

Two studies have indicated that response to rituximab is correlated with steroid response (\(P = .002\) (evidence level Iib))\(^{272}\) or response to previous therapy in general (\(P = .04\) (evidence level Iib)).\(^{275}\) One study found that patients responding to rituximab were older than nonresponders (\(P = .027\) (evidence level III))\(^{272}\) whereas another found no significant difference in age between responders and nonresponders (\(P = .2\) (evidence level Iib)).\(^{275}\) Sex, number of infusions, number of previous treatments, splenectomy, and platelet count did not influence the probability of rituximab response (evidence level Iib, III).\(^{273,275}\)

MMF. In 30 children with primary ITP (newly diagnosed, persistent, or chronic), treatment with MMF achieved a response rate of 56%, and 29% of patients relapsed (evidence level Iib).\(^{277}\) Limited toxicity (asthenia, vomiting, and skin effects in 1 patient each) was observed. Doses were not specified.

**Fostamatinib.** Fostamatinib is not licensed for the treatment of children with ITP and there are no data on its use in children.\(^{180}\)

For more information, see “ITP in adults” > “Subsequent therapy: medical” > “Fostamatinib.”

### Surgical options for children with chronic ITP failing prior therapies

**Recommendations for splenectomy in children with chronic ITP**

1. Splenectomy is very rarely indicated in childhood ITP (Grade C recommendation) and should be undertaken in consultation with a hematologist experienced in the management of children with ITP. It should only be considered in children who have failed all available medical therapies, are having thrombocytopenia-related bleeding, and whose life is at risk or whose HRQoL is substantially impaired.

2. Splenectomy should be avoided if at all possible before 5 years of age and within 1 year of disease onset (Grade C recommendation).

3. Before considering splenectomy, reassess the diagnosis of ITP by excluding alternative diagnoses, including inherited thrombocytopenia, bone marrow failure, drug-induced thrombocytopenia, subclinical viral infections, immunodeficiency syndromes (eg, CVID, autoimmune...
lymphoproliferative syndrome), and myelodysplastic syndrome (Grade C recommendation).

4. Prior to splenectomy, ensure that vaccinations are up to date according to national policy. Vaccination, as a minimum, should include pneumococcal 13-valent conjugate vaccine, followed by pneumococcal 23-valent vaccine 4 weeks later; *H influenzae* type B; and both meningococcal vaccines to cover all 5 species subtypes (Grade C recommendation).

5. If there is any concern for an immunodeficiency-related ITP, even if undocumented, reducing the risk for postsplenectomy sepsis by assessing response to pneumococcal vaccines preprocedure is advisable (Grade C recommendation).

Splenectomy in ITP can achieve high and durable response rates. Since 2010, studies that included adults, as well as children/adolescents, reported initial response rates of 83% to 97% (evidence levels IIb-III)\(^\text{,37,191}\) decreasing to 59% after a median 20-year (range, 10-43) follow-up.\(^\text{37}\) Firm conclusions on splenectomy in children cannot be drawn from the current literature, because studies do not separate results by age or disease duration.

PERISPLENECTOMY MANAGEMENT. Prophylactic anticoagulation and/or antibiotics may be considered for splenectomy in children. Portal vein ultrasound to assess flow may be useful to predict the risk of portal vein thrombosis. The platelet count should be increased to hemostatic levels preoperatively if possible. Splenectomy should be performed laparoscopically. (All evidence level IV.)

POSTSPLENECTOMY MANAGEMENT. As for splenectomy in adults, long-term antibiotic prophylaxis and repeat vaccinations should be given according to national guidelines. The risk of infection in later life should be considered for polysaccharide-encapsulated organisms (eg, pneumococcus), as well as, for example, if the child later works in a school or as a veterinarian or travels to areas with endemic and/or epidemic Babesia, malaria, or dengue. The patient should be advised of the risks of postsplenectomy sepsis and thrombosis (and their appropriate management), to obtain yearly blood counts, and to keep vaccinations up to date.

**Patient-reported outcomes and support of patients with ITP**

The impact of ITP, especially chronic ITP, on patient HRQoL is substantial (evidence level III).\(^\text{278}\) The most difficult ITP symptom to treat is severe fatigue, reported in 39% to 59% of adult patients with ITP,\(^\text{5,279,280}\) yet it is underrecognized by health care practitioners.\(^\text{280}\) ITP leads to impaired HRQoL across emotional, functional, reproductive, and health domains, and it impacts daily living, in turn affecting mental health.

The ITP IWG recommends a treatment goal of a safe platelet count in the absence of bleeding, not a normal platelet count.\(^\text{46}\) Nevertheless, platelet counts remain a focus for health care practitioners, whereas fatigue and mental health aspects are the major concerns of patients. ITP patient support services are provided in numerous countries,\(^\text{281}\) but continued increased awareness of the impact of ITP on HRQoL among health care professionals is required.

**Quality of life of adults with ITP**

**Recommendations for assessment and management of HRQoL outcomes in adults with ITP**

1. A number of scales have been used successfully to assess HRQoL in adults. The ITP-specific 10-scale ITP-patient assessment questionnaire (ITP-PAQ) is a disease-specific questionnaire available as a tool that can be used to measure HRQoL, with estimated minimally important differences (MIDs) aiding interpretation. Additional measures of patient-reported outcomes (PROs) that have been studied in adult patients with ITP include the 36-item Short Form Health Survey (SF-36), EuroQol tool (EQ-5D), Hamilton anxiety and expression rating scales, Motivation and energy inventory-short form (MEI-SF), Fatigue subscale of the functional assessment of chronic illness therapy (FACT-Fatigue), and Functional assessment of cancer therapy–thrombocytopenia (FACT-Th6) (Grade C recommendation).

2. Impaired HRQoL is multifactorial and includes (but is not limited to) issues around actual bleeding, fear of bleeding, reduced energy, depression, treatment side effects, and additive influences of underlying or comorbid diseases (Grade C recommendation).

3. Patients responding to treatment have improved HRQoL, with responders to TPO-RA improving more than responders to other therapies (evidence levels Ib, III); romiplostim may improve fatigue in responders (evidence level Ib) (Grade A recommendation).

4. PROs are essential outcome measures for clinical trials and should be considered in the routine management of children and adults with ITP.

Different tools to assess HRQoL and PROs in adults with ITP are available.\(^\text{282}\) These include ITP-PAQ,\(^\text{10}\) developed specifically for assessing HRQoL in ITP patients, EQ-5D index score,\(^\text{283}\) SF-36,\(^\text{284}\) Hamilton anxiety and depression rating scales,\(^\text{278}\) MEI-SF,\(^\text{285}\) FACT-Fatigue,\(^\text{285}\) and FACT-Th6, a 6-item subset of FACT-Th.\(^\text{285}\)

PRO tools have been developed and validated using different methodologies. The domains measured by each PRO and the time period over which a change can be detected vary. When using a PRO outside of the geographical region in which it was developed, a validation of cultural and language changes are desirable. Consideration of which PRO tool to use should reflect the population being assessed and the time period in which to expect changes; ideally, >1 validated tool should be used.

To understand the clinical significance of changes in the ITP-PAQ score, MIDs have been calculated.\(^\text{286}\) MID values of 8 to 12 are considered clinically significant for the following scales: Symptoms, Bother, Psychological, Overall HRQoL, Social Activity, Menstrual Symptoms, and Fertility. For Fatigue and Activity, MID values of 10 to 15 were considered clinically significant. These estimates were consistent with moderate effect sizes. However, MIDs were not estimable for the scales Fear and Work.\(^\text{286}\)
Patients with ITP have been shown to have statistically significantly worse outcomes than the general population with regard to general fatigue, physical fatigue, reduced activity, and mental fatigue, as assessed by SF-36 (evidence level IIb).\textsuperscript{284} Higher fatigue severity was associated with poorer physical and mental HRQoL outcomes. Patients with persistent ITP were shown to have clinically meaningful impairments in physical functioning, social functioning, role physical, role emotional, and mental health scales (evidence level IIb).\textsuperscript{284} In 1 study, patients with chronic ITP appeared to be most affected by reduced work ability, fear, bleeding, and fatigue (evidence level III), \textsuperscript{72} 72% expressed some degree of depression, and 21% reported some degree of anxiety.\textsuperscript{278}

**Treatment and HRQoL.** In 1 study of adults with chronic ITP, the use of SF-36 found that treatment did not generally impact HRQoL (evidence level II).\textsuperscript{278} Platelet and red blood cell transfusions, splenectomy, and corticosteroid side effects, in particular, did not influence HRQoL, whereas treatment with IVIg increased bodily pain.\textsuperscript{278} However, a study of patients’ and hematologists’ perspectives of corticosteroid side effects in ITP found that patients reported severe side effect symptoms significantly more frequently than did hematologists (evidence level II).\textsuperscript{287} Patients also frequently responded that the corticosteroid side effects resulted in “a lot of bother,” the highest level of severity.\textsuperscript{287}

**ROMIPLOSTIM.** The effect of romiplostim on HRQoL has been evaluated in 3 studies: 2 using ITP-PAQ and 1 using EQ-5D (evidence level Ib).\textsuperscript{10,283,288} All studies reported improvement in HRQoL for patients responding to romiplostim vs nonresponders, although differences were not always significant or greater than MIDs, and response criteria varied.\textsuperscript{10,283,286} Responders to romiplostim and standard of care showed an improvement in fatigue above MIDs.\textsuperscript{10}

Compared with standard of care, patients receiving romiplostim showed a significant (and greater than MID) improvement over baseline in symptoms, bother, psychological health, and overall HRQoL on the ITP-PAQ; however, there was no significant difference in fatigue.\textsuperscript{10} Splenectomized patients receiving romiplostim showed significantly greater improvements in HRQoL vs placebo on the ITP-PAQ for symptoms, bother, social activity, and women’s reproductive health. Nonsplenectomized patients treated with romiplostim showed only a significant improvement in activity vs placebo.\textsuperscript{288}

**ELTROMBOPAG.** The effect of eltrombopag on HRQoL in adults with ITP lasting ≥6 months has been evaluated in the RAISE and EXTEND studies using 4 instruments: SF-36v2, MEI-SF, FACIT-Fatigue, and FACT-Th6.\textsuperscript{149,285} In the RAISE study, at week 26 several scores were significantly improved from baseline in patients receiving eltrombopag (5 of 8 SF-36v2 scores, both SF-36v2 summary scores, and FACT-Th6) (evidence level Ib).\textsuperscript{149} Improvements were significantly associated with eltrombopag-mediated increases in platelet count and decreases in bleeding (World Health Organization scale).\textsuperscript{149} In the EXTEND study (all patients receiving eltrombopag), depending on the instrument used, 80% to 85% of patients experienced an improvement in HRQoL vs baseline; clinically meaningful improvement vs baseline was observed at least once during eltrombopag treatment in 48% to 64% of patients (evidence level III).\textsuperscript{285} Improvement from baseline in some measures of HRQoL (FACIT-Fatigue and FACT-Th6) persisted for up to 5 years, although the improvement was not significant at all time points.\textsuperscript{285}

**Quality of life of children with ITP**

**Recommendations for assessment and management of HRQoL outcomes in children with ITP**

1. HRQoL should be reported using the Kid’s ITP Tool (KIT; or another validated scale) before and after treatment, to assess the effect of treatment beyond the platelet count (Grade C recommendation).
2. HRQoL of children with newly diagnosed ITP improves on disease resolution (evidence level Ila; Grade B recommendation).
3. Corticosteroids may worsen HRQoL in children (evidence level Ila; Grade B recommendation).
4. TPO-RAs may improve HRQoL of children with ITP, and romiplostim especially appears to improve parental burden (evidence level Ib, Ila; Grade B recommendation).

KIT, developed in 2007,\textsuperscript{289} is ITP specific and consists of child self-reporting (for children aged ≥7 years), parent proxy reporting, and assessment of parent impact.\textsuperscript{290} The established, but non-ITP specific, Pediatric Quality of Life Inventory (PedsQL) questionnaire may also be used. HRQoL is harder to assess in children than in adults; irritability or depression may be observed instead of fatigue.

In a study of children with newly diagnosed ITP, KIT and PedsQL were used at diagnosis and at follow-up appointments (evidence level Ila).\textsuperscript{291} Results of PedsQL were comparable with healthy children. KIT proxy reports and parent self-reports showed significantly higher HRQoL scores in children who recovered than in those with persistent ITP at 3 or 6 months. There was no significant difference in HRQoL by KIT or PedsQL between children with mild vs moderate bleeding (evidence level Ila).\textsuperscript{291}

**Treatment and HRQoL.** In 1 study, HRQoL was compared in children receiving treatment and those managed through observation (evidence level Ila).\textsuperscript{292} HRQoL (assessed by KIT) was not improved through treatment (IVIg, prednisone, IVIg plus steroids, anti-D, rituximab, or splenectomy); the lowest KIT scores were observed after treatment with prednisone. The parent-proxy KIT scores were significantly worse for newly diagnosed children receiving treatment, particularly prednisone. Thus, the side effects of treatment appear to negatively impact HRQoL and outweigh the benefits of an increased platelet count (evidence level Ila).\textsuperscript{292}

Another study showed that HRQoL (by KIT and PedsQL) of newly diagnosed children with ITP was not significantly different between those randomized to observation vs IVIg (evidence level Ila).\textsuperscript{291}

**ROMIPLOSTIM.** Two studies have shown that romiplostim may improve HRQoL (as assessed by KIT) in children with ITP lasting ≥6 months.\textsuperscript{290,293} One reported no significant difference, and the other reported numerically greater and occasionally significant improvements, in child self-reported HRQoL over baseline with romiplostim vs placebo (evidence levels Ib, Ila).\textsuperscript{290,293} Romiplostim significantly reduced parental burden vs placebo in both studies.

**ELTROMBOPAG.** The impact of eltrombopag on HRQoL in children with persistent or chronic ITP was evaluated in the Petit trial (evidence level Ib).\textsuperscript{294} There was a wide variability in KIT scores at
baseline. Small improvements in HRQoL were noted in responders to eltrombopag aged 1 to 5 years and 12 to 17 years but not those in who were 6 to 11 years old. Therefore, eltrombopag did not appear to substantially affect HRQoL of children, as assessed by KIT.

Support for children with ITP. A survey of 278 pediatric hematologists or oncologists revealed a large variation in the perceived contact risk for different sports and in the advice offered about restricting sporting activities in children with ITP (evidence level III). Most physicians recommended restricting sport activity at platelet counts < 50 x 10^9/L, and only one third would encourage perceived low-risk sport (eg, golf, dancing, swimming). The current perceptions and advice given could negatively impact HRQoL in a generally benign disease; thus, decision making should be patient focused (evidence level III). A recent review article on sports participation for patients with bleeding disorders recommends maintaining a healthy level of safe participation in different activities. The recommendations below are based on national and organization guidelines.

Recommendations for school and participation in sporting activities for children with ITP

1. Children and adolescents 5 to 18 years old need ≥60 minutes of physical activity per day, ≥3 d/wk. This should include exercises or sports to promote strong muscles and bones (Grade C recommendation).
2. Normal attendance and play at kindergarten, school, or college, depending on age, is essential. The risk of bleeding and information about ITP should be provided to the school in a way that facilitates inclusion, not isolation (Grade C recommendation).
3. Active participation in low-risk activities should be maintained, irrespective of platelet count and treatment (Grade C recommendation).
4. Participation in nonlow-risk activities must be discussed with the family, school, and coach. A number of factors must be considered prior to participation, including age of the child, platelet count, bleeding history, and physical nature of the activity (Grade C recommendation).
5. Participation in high-risk activities (including BMX racing, boxing, American football, ice hockey, lacrosse, motorcycle racing, motocross racing, power lifting, outdoor rock climbing, rodeo, rugby, snowmobiling, trampoline, and wrestling) should be discouraged unless the patient has a near-normal platelet count on a consistent and stable basis. Alternatively, treatment should be administered to provide a safe platelet count during the activity (Grade C recommendation).
6. Intermittent or continuous treatment may be given to cover activities with appropriate discussion of risks vs benefits of the activity and treatment, with emphasis on psychological well-being and risks for injury, despite treatment (Grade C recommendation).
7. Choice of treatment and target platelet count must be carefully evaluated based on extensive consultation with the family and consideration of the specific activity desired and the bleeding tendency of the child (Grade C recommendation).

Conclusions

This consensus report provides a timely update to the previous report published in 2010. Based on the new evidence available, and the authors' expert opinion, updates to the recommendations and the supporting evidence are presented. Should it become apparent that this consensus report requires further update, the panel will reconvene to discuss how best to do this.

Although there are numerous publications on the diagnosis and treatment of ITP, knowledge gaps remain, and up-to-date expert opinion and experience are key.

Acknowledgments

Professional medical writing support was provided by Lyndsey Kostadinov and Anne Carter of Medicalwriters.com.

This work was supported by unrestricted educational grants from Amgen, Novartis, and Rigel.

Authorship

Conflict-of-interest disclosure: D.P. has received research support and honoraria from Amgen and Novartis and has acted as a consultant for UCB, MedImmune, and Ono. D.M.A. has received research funding from Novartis, Bristol-Myers Squibb, and Rigel and has acted as a consultant for Novartis, Principia, and Rigel. J.B.B. has acted as a consultant (including serving on advisory boards) for Amgen, Novartis, Dova Pharmaceuticals, UCB, argenx, Momenta, Rigel, Tranquil, Regeneron Pharmaceuticals, Octapharma, Kezar, and the PDSA. B.H.C. has received honorarium from Novartis for participating in the speaker's forum. N.C. has received honoraria for educational speaking events and for serving on advisory boards for Novartis, Amgen, Rigel, and Principia and has acted as the chief investigator or principal investigator of clinical trials for Amgen, Novartis, Rigel, Principia, and UCB. T.G. has received honorarium from Amgen; has acted as a consultant for Amgen, Dova Pharmaceuticals, Biogen, Cellphere, Fujifilm, Rigel, Shionogi, and Principia; and has received research support from Principia. W.G. has received research grants from Novartis, Bayer, and BMS/Pfizer; has received lecture honoraria from Novartis, Amgen, and Bayer; and has acted as a consultant for Amgen, Novartis, and MSD. B.G. has served as an expert for Amgen and Novartis and has received research funds from Amgen and Roche. T.I.G.-L. has received research grants and speaker honoraria from Amgen and Novartis. J.G. has received honoraria (speaker fees, travel grants) from Amgen and Novartis and has acted as a consultant for Amgen, Novartis, Ono, Alexion, and Biotest. C.K. has acted as a consultant for Novartis and UCB; has received honoraria from Amgen (paid to PDSA); PDSA funding from Amgen, argenx, Dova, Novartis, Momenta, Principia, Octapharma, CSL Behring, Rigel, and UCB; and is a board member of the Thrombosis & Hemostasis Societies of North America. V.M. has acted as a consultant for AbbVie and has received honoraria from Bayer, Novartis, and Amgen. M.M. has received consultancy fees/honoraria (for serving on advisory boards and/or for being a member of the speakers bureau) from Amgen, Novartis, and Rigel in the last 2 years. A.C.N. has acted as a consultant for and has received honoraria directly from Amgen, Anglogene, Dova Pharmaceuticals, Novartis, Ono, Rigel, and Shionogi; has received funding from Amgen, Novartis, and Rigel; and has
provided paid expert testimony for argenx and Rigel. S.P. has received fees for lectures, chairing sessions, and serving on advisory boards. F.R. has been a member of the speakers bureau/consultant/advisory board for Amgen, Novartis, and argenx. M.S. has received honoraria from Novartis for serving on its advisory board and for being a member of its speakers bureau. Y.T. has acted as a consultant for Sysmex and has received honoraria from Novartis, Kyowa Kirin, and Chugai. R.S.W. has received research funding from Amgen, Apellis Pharmaceuticals, Bayer, Boehringer-Ingelheim, Biogen-Idec, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, and Sanofi and has acted as a consultant for Alexion, Amgen, Bayer, Boehringer-Ingelheim, Kyowa Kirin, and Novartis. F.Z. has received research funding from Novartis, Celgene, AbbVie, Amgen, and Janssen Cilag and has received honoraria for participating on advisory board and/or for presenting talks at meetings from Novartis, Celgene, AbbVie, Amgen, Janssen Cilag, Sandoz, Takeda, and Roche. D.J.K. has received research funding from Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios Pharmaceuticals, Syntimmune, Principia, and Alnylam Pharmaceuticals and has acted as a consultant for Ono Pharmaceutical, Pfizer, 3SBio, Eisai, GlaxoSmithKline, Genzyme, Shire, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Alexion, Bioverativ, Argex, Zafgen, Fujifilm, Principia, Kyowa Kirin, Takeda, and the Platelet Disorders Support Group. M.H. declares no competing financial interests.

**References**

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010;115(2):168-186.

2. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011;117(16):4190-4207.

3. Vernooy RW, Alonso-Coello P, Brouwers M, Martinez Garcia L; CheckUp Panel. Reporting items for updated clinical guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp). *PLoS Med*. 2017;14(1):e1002207.

4. Arnold DM, Nazy I, Clare R, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. *Blood Adv*. 2017;1(25):2414-2420.

5. Tamminga R, Berchtold W, Bruin M, Buchanan GR, Kühne T. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). *Br J Haematol*. 2009;146(2):180-184.

6. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. *Arch Dis Child*. 2001;84(3):227-229.

7. Grimaldi-Bensouda L, Michel M, Aubrun E, et al; PGRx Immune Thrombocytopenia Study Group. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. *Blood*. 2012;120(25):4938-4944.

8. Grimaldi-Bensouda L, Nordon C, Michel M, et al; Group for the PGRx-ITP Study. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. *Haematologica*. 2016;101(9):1039-1045.

9. Newton JL, Reese JA, Watson SI, et al. Fatigue in adult patients with primary immune thrombocytopenia. *Eur J Haematol*. 2011;86(5):420-429.

10. Kuter DJ, Mathias SD, Rummel M, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. *Am J Hematol*. 2012;87(5):558-561.

11. Hill QA, Newland AC. Fatigue in immune thrombocytopenia. *Br J Haematol*. 2015;170(2):141-149.

12. Mant MJ, Connolly T, Gordon PA, King EG. Severe thrombocytopenia probably due to acute folic acid deficiency. *Citr Care Med*. 1979;7(7):297-300.

13. Mishra VA, Harbada R, Sharma A. Vitamin B12 and vitamin D deficiencies: an unusual cause of fever, severe hemolytic anemia and thrombocytopenia. *J Family Med Prim Care*. 2015;4(1):145-148.

14. Braester A. Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocytethemia. *Eur J Haematol*. 2003;70(4):251-252.

15. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. *Blood*. 1996;88(1):3-40.

16. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. *Br J Haematol*. 2003;120(4):574-596.

17. Mak YK, Yu PH, Chan CH, Chu YC. The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation? *Clin Lab Haematol*. 2000;22(6):355-358.

18. Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. *Clin Appl Thromb Hemost*. 2002;8(1):79-76.

19. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. *Haematologica*. 2008;93(1):151-152.

20. Rizvi H, Butler T, Calaminici M, et al. United Kingdom immune thrombocytopenic purpura registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenic purpura and correlation with clinical findings. *Br J Haematol*. 2015;169(4):590-594.
21. Brynes RK, Wong RS, Thein MM, et al. A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia. Acta Haematol. 2017;137(2):66-72.

22. Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95(7):1077-1087.

23. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231-1240.

24. Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):557-573.

25. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J; ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76(3):205-213.

26. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194-201.

27. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1(3):485-491.

28. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins Ib/IIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122(5):818-824.

29. Al-Samkari H, Rosovsky RP, Karp Leal RS, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Am J Hematol. In press:0361-8609.

30. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84(12):4203-4208.

31. Kim KJ, Baek W, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol. 2013;161(5):706-714.

32. Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol. 2008;142(4):639-643.

33. Ruggeri M, Tosetto A, Palandri F, et al; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12(8):1266-1273.

34. Altintas A, Ozel A, Okur N, et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2007;24(2):163-168.

35. Moulin G, Germain J, Comont T, et al; CARMEN Investigators Group. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493-500.

36. Khellaf M, Chabrol A, Mahevas M, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89(2):194-198.

37. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98(6):875-880.

38. Guan Y, Wang S, Xue F, et al. Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol. 2017;98(3):235-241.

39. Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol. 2018;181(2):183-195.

40. Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44(4 suppl 5):S24-S34.

41. O’Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129(2):248-255.

42. Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12):1041-1044.

43. Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501-1508.

44. Abe Y, Wada H, Tomatsu H, et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res. 2006;118(4):463-469.

45. Cybulaska A, Meintker L, Ringwald J, Krause SW. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. Br J Haematol. 2017;177(4):612-619.

46. Levi M, Toh CH, Thachj J, Watson HG; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33.

47. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100(2):710-713.

48. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
49. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. *Blood*. 2013;121(23):4782-4790.

50. Piel-Julian ML, Mahévas M, Germain J, et al; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. *J Thromb Haemost*. 2018;16(9):1830-1842.

51. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. *Blood*. 2001; 97(9):2549-2554.

52. Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoietin receptor agonist therapy in thrombocytopenia: ITP and beyond. *Br J Haematol*. 2017;177(3):475-480.

53. Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient. *Transfusion*. 2015;55(10):2505-2510.

54. Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. *Br J Haematol*. 2018;182(1): 106-113.

55. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. *Arch Intern Med*. 2000;160(11):1630-1638.

56. Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. *Br J Haematol*. 2019;185(3):503-513.

57. Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. *Blood*. 2016;128(12):1547-1554.

58. Mahévas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. *Br J Haematol*. 2016;173(6):844-856.

59. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. *Trans Assoc Am Physicians*. 1965;78:374-390.

60. Germsholmer T, Stratton J, Baile PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. *N Engl J Med*. 1989;320(15):974-980.

61. Kitchens CS, Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. *Blood*. 1975;46(4):567-578.

62. Kitchens CS. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. *J Clin Invest*. 1977;60(5):1129-1134.

63. Matschke J, Müller-Beissenhirtz H, Novotny J, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 Study. *Acta Haematol*. 2016;136(2):101-107.

64. Nakazaki K, Hosoi M, Hangaiishi A, Ichikawa M, Nannya Y, Kurokawa M. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. *Intern Med*. 2012;51(8):859-863.

65. Praituan W, Rojnuckarin P. Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. *J Thromb Haemost*. 2009;7(6):1036-1038.

66. Bilgir O, Bilgir F, Kebapcilar L, et al. Comparison of conventional dose steroid treatment and high dose steroid treatment as run-in regime for splenectomy in immune thrombocytopenic purpura (ITP). *Transfus Apheresis Sci*. 2011;44(3):239-242.

67. Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia. *Platelets*. 2010;21(4):270-273.

68. Sakamoto K, Nakasone H, Tsurumi S, et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. *J Thromb Thrombolysis*. 2014;37(3):279-286.

69. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. *Blood*. 2016;127(3):296-302, quiz 370.

70. Miethowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. *Lancet Haematol*. 2016;3(10):e489-e496.

71. Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. *Eur J Haematol*. 2013;90(6):494-500.

72. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. *Blood*. 2013;121(11):1976-1981.

73. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. *Blood*. 2010;115(14):2755-2762.

74. Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. *Am J Hematol*. 2016;91(9):907-911.

75. Bussel JB, Lee CS, Seery C, et al. Rituximab and three-dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. *Haematologica*. 2014;99(7):1264-1271.

76. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. *Lancet Haematol*. 2015;2(2):e75-e81.
77. Alpdogan O, Budak-Alpdogan T, Ratip S, et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol. 1998;103(4):1061-1063.

78. von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Leeie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988;296(6617):249-250.

79. Kovaleva L, Apte S, Damodar S, et al; investigators of the Flebogamma DIF in ITP Study Group. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. Immunotherapy. 2016;8(12):1371-1381.

80. Spadarro G, Vultaggio A, Alberto Bosi A, et al. Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia [published correction appears in Int Immunopharmacol. 2018;57:201]. Int Immunopharmacol. 2017;44:38-42.

81. Frenzel W, Wietek S, Svae TE, Debes A, Svorc D. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54(11):847-855.

82. Robak T, Mainau C, Pyringer B, et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia. Hematology. 2010;15(5):351-359.

83. Robak T, Salama A, Kovaleva L, et al; International Privigen in ITP Study Group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.

84. Dash CH, Gillanders KR, Stratford Bobbitt ME, Gascoigne EW, Leach SJ. Safety and efficacy of Gammalax® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov–NCT00504075). PLoS One. 2014;9(6):e96600.

85. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):597-504.

86. Paziana K, Del Monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279-294.

87. Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica. 2007;92(2):283-284.

88. al-Samkari M, Cafferty F, Al-Samkari M, et al. Platelet antibody testing in immune thrombocytopenia and Evan’s syndrome: longitudinal serological evolution and relation to clinical features. Blood. 2018;132(suppl 1):1137.

89. Naithani R, Kumar R, Mahapatra M, Tyagi S, Saxena R. Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia. Platelets. 2009;20(7):525-527.

90. Sael Therapeutics Inc. WinRho SDF prescribing information. June 2018.

91. Despotovic JM, Lambert MP, Herman JH, et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion. 2012;52(5):1126-1136, quiz 1125.

92. Stirnemann J, Kaddouri N, Khelfa M, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96(3):269-275.

93. Khelfa M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90(6):829-832.

94. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596-2606.

95. Goel R, Chopra S, Tobian AAR, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169-176.

96. Estcourt LJ, Birchall J, Allard S, et al; British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365-394.

97. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80(6):1051-1054.

98. Spahr YH, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122-125.

99. Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. Int J Hematol. 2016;103(2):180-188.

100. Ahn YS, Harrington WJ, Mylvaganam R, Allen LM, Pall LM. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med. 1984;100(2):192-198.

101. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med. 1974;291(8):376-380.

102. Facer T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fenaux P. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994;86(3):678-680.

103. Fenaux P, Quinquand I, Caulier MT, Simon M, Walter MP, Bauters F. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases. Blut. 1990;60(4):238-241.

104. Fresneau B, Petit A, Courcoux MF, et al. Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. Am J Hematol. 2011;86(9):785-787.
105. Manoharan A. Targeted-immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia. *Aust N Z J Med.* 1991;21(4):405-407.

106. Massimo L, Genova R, Marchi A, Masera G, Massolo I, Mori PG. More on vincristine in treatment of ITP in children. *N Engl J Med.* 1977;297(7):397-398.

107. Nomura T, Maekawa T, Uchino H, et al. Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. *Nippon Ketsueki Gakkai Zasshi.* 1990;53(1):98-104.

108. Pizzuto J, Ambirz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. *Blood.* 1984;64(6):1179-1183.

109. Sikorska A, Słomkowski M, Marinka K, Konopka L, Goski T. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. *Clin Lab Haematol.* 2004;26(6):407-411.

110. Strenemann J, Vigan M, Hamroun D, et al. The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients. *Orphanet J Rare Dis.* 2012;7(1):77.

111. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). *Blood.* 2007;110(10):3526-3531.

112. Wardrop D, Estcourt LJ, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. *Cochrane Database Syst Rev.* 2013;(7):CD009733.

113. Newland A, Goddeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. *Br J Haematol.* 2016;172(2):262-273.

114. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. *Thromb Haemost.* 2008;99(1):4-13.

115. Sailer T, Lechner K, Panzer S, Kylie PA, Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. *Haematologica.* 2006;91(8):1041-1045.

116. Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ. Remissions after long-term use of romiplostim for immune thrombocytopenia. *Haematologica.* 2016;101(12):e476-e478.

117. Wong RSM, Saleh MN, Khellf A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. *Blood.* 2017;130(23):2527-2536.

118. DOPELET. DOPELET® (avatrombopag) tablets, for oral use [prescribing information]. Durham, NC: Dova Pharmaceuticals; 2019.

119. Nplate. Nplate (romiplostim) [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2018.

120. NPLATE. NPLATE® (romiplostim) for injection, for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2018.

121. PROMACTA. PROMACTA® (eltrombopag) tablets, for oral use; PROMACTA® (eltrombopag) for oral suspension [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

122. Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. *Haematologica.* 2017;102(8):1342-1351.

123. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. *Haematologica.* 2010;95(7):1167-1175.

124. Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). *J Thromb Haemost.* 2010;8(6):1372-1382.

125. Janssens A, Tarantino M, Bird RJ, et al. Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity. *Acta Haematol.* 2015;134(4):215-228.

126. Stasi R, Murali M, Michel M, et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. *Int J Hematol.* 2012;96(1):26-33.

127. Shirasugi Y, Ando K, Miyazaki K, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). *Int J Hematol.* 2012;95(6):652-659.

128. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. *Int J Hematol.* 2011;94(1):71-80.

129. Pullarack VA, Gernsheimer TB, Wasser JS, et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). *Am J Hematol.* 2009;84(8):538-540.

130. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. *Br J Haematol.* 2013;161(3):411-423.

131. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. *N Engl J Med.* 2010;363(20):1889-1899.

132. Michel M, Wasser J, Godeau B, et al. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia. *Ann Hematol.* 2015;94(12):1973-1980.

133. Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. *Eur J Haematol.* 2017;98(2):112-120.
134. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-2171.

135. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259-270.

136. Park S, Yoon SS, Lee JH, Park JS, Jang JH, Lee JW. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia. Int J Hematol. 2016;103(1):44-52.

137. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338-4345.

138. Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881-887.

139. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.

140. Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018;84(11):2673-2677.

141. Revolade. Revolade (olamine) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited; 2018.

142. González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol. 2017;106(4):508-516.

143. Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799-806.

144. Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101-110.

145. Scully M, Kaczmarski R, Myers B, Collins R, Emohare O, Bolton-Maggs PH. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia. Br J Haematol. 2012;157(2):259-260.

146. Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013;24(3):284-296.

147. Katsutani S, Tomiyama Y, Kimura A, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013;98(3):323-330.

148. Kuter DJ, Macahilig A, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3):255-263.

149. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393-402.

150. Bussel JB, Provan D, Shamli T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641-648.

151. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013;160(4):538-546.

152. González-López TJ, Álvarez-Román MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297-302.

153. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol. 2015;90(7):598-601.

154. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40-E40.

155. Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytepoiesis. Exp Hematol. 2008;36(10):1337-1342.

156. Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247-254.

157. Al-Samkari H, Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol. 2018;183(2):168.

158. Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-ranging, placebo-controlled Phase 1 studies. Br J Haematol. 2018;183(3):468-478.

159. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887-3894.

160. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.

161. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
162. Al Askar AS, Shaheen NA, Al Zahrani M, et al. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. Int J Hematol. 2018;107(1):69-74.

163. Miyakawa Y, Katsutani S, Yano T, et al. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015;102(6):654-661.

164. Maranong M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371-377.

165. Červenek L, Černá O, Čaniga M, et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol. 2012;96(5):594-599.

166. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocytopenic purpura. J Thromb Thombolyis. 2009;27(3):329-333.

167. Ghanima W, Khelil A, Waage A, et al; RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653-1661.

168. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228-3236.

169. Arnold DM, Hedde NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356-1362.

170. Mahévas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013;88(10):858-861.

171. Tran H, Brightton T, Grigg A, et al. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243-251.

172. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329-334.

173. Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87(8):866-868.

174. Serris A, Amoura Z, Canouil-Poirine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytophenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93(3):424-429.

175. RITUXAN® (rituximab) injection, for intravenous use [prescribing information]. South San Francisco, CA: Genentech; 2018.

176. MabThera. MabThera (rituximab) [summary of product characteristics]. Grenzach-Wyhlen, Germany: Roche Registration GmbH; 2018.

177. Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux [published online ahead of print 5 September 2019]. Am J Hematol. doi:10.1002/ajh.25632.

178. Gracie C, Abbas Z, Dooberee U, et al. Comparison of standard and low dose rituximab in primary immune thrombocytopenia: data from the UK ITP Registry. EHA Library. 2018;214559:S139.

179. Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11): 1946-1953.

180. TAVALISSE. TAVALISSE™ (fosmatitinib disodium hexahydrate) tablets, for oral use [prescribing information]. South San Francisco, CA: Rigel Pharmaceuticals Inc; 2018.

181. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.

182. Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546-553.

183. Dammika G, Nipunika S, Yasintha C, Jayan SS, Indira W. Identifying the characteristics, natural behavioral pattern, and response to therapy in ITP in a multi-center population in Sri Lanka. Hematology. 2016;21(6):375-378.

184. Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222-228.

185. Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727-733.

186. Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol. 2012;87(3):321-323.

187. Colella MP, Alves ECF, de França Delmoro G, et al. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: efficacy, safety and factors associated with treatment response. Blood. 2018;132:737.

188. Colović M, Suvadžić N, Colović N, Tomin D, Vidović A, Palibrk V. Mycophenolate mofetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153-156.

189. Taylor A, Neave L, Solangi S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625-630.

190. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84(10):661-665.
191. Chen X, Peng B, Cai Y, et al. Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary? J Surg Res. 2011;170(2):e225-e232.

192. Zaja F, Barcellini W, Canton I, et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol. 2016;91(5):E293-E295.

193. Park YH, Yi HG, Kim CS, et al; Gyeonggi/ncheon Branch, The Korean Society of Hematology. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary thrombocytopenia: a multicenter retrospective study. Acta Haematol. 2016;135(3):162-171.

194. Tada K, Ohta M, Saga K, et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today. 2018;48(2):180-185.

195. Chater C, Terriou L, Duhamel A, et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016;264(5):772-777.

196. Moulias G, Sailer L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol. 2014;89(1):41-46.

197. Vecchio R, Marchese S, Intagliata E, Swehl F, Erfa L, Cacciola E. Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. J Laparoendosc Adv Surg Tech A. 2013;23(3):192-198.

198. Sarpatwari A, Provan D, Erogu S, Sobnack R, David Tai FW, Newland AC. Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol. 2010;151(5):477-487.

199. Cuker A, Cines DB. Evidence-based mini-review: is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? Hematology (Am Soc Hematol Educ Program). 2010;2010(1):385-386.

200. Mahévas M, Van Eckhoudt S, Moulias G, et al. Autologous111 indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol. 2019;186(3):e44-e47.

201. Palandri F, Polverelli N, Catani L, et al. The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study. Am J Hematol. 2014;89(11):1047-1050.

202. Qu Y, Xu J, Jiao C, Cheng Z, Ren S. Long-term outcomes of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura. Int Surg. 2014;99(3):286-290.

203. Mohamed SY, Abdel-Nabi I, Imam A, et al. Systemic thromboembolic complications after laparoscopic splenectomy for idiopathic thrombocytopenic purpura in comparison to open surgery in the absence of anticoagulant prophylaxis. Hematol Oncol Stem Cell Ther. 2010;3(2):71-77.

204. Ray U, Gupta S, Chatterjee S, SenGupta TK, Gupta NK. Laparoscopic versus open splenectomy in the treatment of idiopathic thrombocytopenic purpura: an Indian experience. J Indian Med Assoc. 2012;110(12):889-893.

205. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-1506.

206. Thai LH, Mahévas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48):e5098.

207. Morbier C, Brunetti F, Baranès L, et al. Systematic detection of portal or splenic vein thrombosis after splenectomy for immune cytopenia. Am J Hematol. 2018;93(7):E170-E172.

208. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99(2):392-398.

209. Togasaki E, Shimizu N, Nagao Y, et al. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Ann Hematol. 2018;97(4):655-662.

210. Lakhwani S, Perera M, Fernández-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372-377.

211. González-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111-116.

212. Thanarajasingam G, Vaidya R, Erie A, Wolanskyj AP. Accessory splenectomy for refractory immune thrombocytopenic purpura. Am J Hematol. 2011;86(6):520-523.

213. Choi YU, Domínguez EP, Sherman V, Sweeney JF. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. JSLS. 2008;12(3):314-317.

214. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29-31.

215. Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy. 2001;3(3):189-195.

216. Gómez-Almaquar D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783-4785.

217. Lete I, Obispo C, Igaurre I, et al; Spanish Society of Gynaecology Obstetrics (SEGO). The levonorgestrel intracutaneous system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care. 2008;13(3):231-237.

218. Care A, Pavord S, Knight M, Alferevic Z. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. BJOG. 2018;125(5):604-612.
219. Loustau V, Debouverie O, Canouí-Politine F, et al. Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014;166(6):929-935.
220. Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. N Engl J Med. 2018;379(1):32-43.
221. Reese JA, Peck JD, Yu Z, et al. Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy. Am J Hematol. 2019;94(1):E8-E11.
222. Zhang X, Zhao Y, Li X, et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget. 2018;7(7):7489-7496.
223. Wang X, Xu Y, Luo W, et al. Thrombocytopenia in pregnancy with different diagnoses: differential clinical features, treatments, and outcomes. Medicine (Baltimore). 2017;96(29):e7561.
224. Kasai J, Aoki S, Kamiya N, et al. Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy. J Obstet Gynaecol Res. 2015;41(1):44-49.
225. Michel M, Novoa MV, Bussel JB. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol. 2003;123(1):142-146.
226. Sun D, Shehata N, Ye XY, et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016;128(10):1329-1335.
227. Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097-1103.
228. Nataraj A, Popco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57(12):1401-1402.
229. CELLECEPT, CELLCEPT® (mycophenolate mofetil) capsules, for oral use; CELLCEPT® (mycophenolate mofetil) tablets, for oral use; CELLCEPT® Oral Suspension (mycophenolate mofetil), for oral suspension; CELLCEPT® Intravenous (mycophenolate mofetil) for injection, for intravenous use [prescribing information]. South San Francisco, CA: Genentech; 2019.
230. Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231-1235.
231. Purushothaman J, Puthuman KA, Kumar A, Innah SJ, Gilvaz S. A case of refractory immune thrombocytopenia in pregnancy managed with eltrombopag. Asian J Transfus Sci. 2016;10(2):155-158.
232. Decrooq J, Marcellin L, Le Ray C, Willems L. Rescue therapy with romiplostim for refractory primary immune thrombocytopoenia during pregnancy. Obstet Gynecol. 2014;124(2 Pt 2 suppl 1):481-483.
233. Patil AS, Dotters-Katz SK, Metjian AD, James AH, Swamy GK. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy. Obstet Gynecol. 2013;122(2 Pt 2):483-485.
234. Suzuki N, Hiraga J, Hariyama Y, et al. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag. Int J Hematol. 2018;108(1):109-111.
235. Alkaabji JK, Alkindi S, Ryami NA, Zia F, Balla LM, Balla SM. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus. 2012;21(14):1571-1574.
236. Rosa Maria RN, Laura RL, Angeles PB, Laura LB. Use of romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: literature review and case description [published online ahead of print 22 May 2019]. Platelets. doi:10.1080/09537104.2019.1615613.
237. Ferreira UMCF, Sousa F, Vasco EM, et al. Severe immune thrombocytopenia in pregnancy treated with eltrombopag - a case report. J Gynecol Obstet Hum Reprod. 2018;47(8):405-408.
238. Lee LO, Bateman BT, Kheretalp S, et al; Multicenter Perioperative Outcomes Group Investigators. Risk of epidural hematoma after neuraxial techniques in thrombocytopenic parturients: a report from the Multicenter Perioperative Outcomes Group. Anesthesiology. 2017;126(6):1053-1063.
239. Payne SD, Resnik R, Moore TR, Hedhiana HL, Kelly TF. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage complicated by autoimmune thrombocytopenia. Am J Obstet Gynecol. 1997;177(1):149-155.
240. Bader-Meunier B, Proule V, Trichet C, et al. Misdiagnosis of chronic thrombocytopenia in childhood. J Pediatr Hematol Oncol. 2003;25(7):548-552.
241. Kottayam R, Rozenberg G, Brighton T, Cohn RJ. Isolated thrombocytopenia in children: thinking beyond idiopathic thrombocytopenic purpura and leukaemia. J Paediatr Child Health. 2007;43(12):848-850.
242. Kalpathi R, Bussel JB. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr. 2008;20(1):8-16.
243. Noris P, Klersy C, Gresele P, et al; Italian Gruppo di Studio delle Piastrine. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br J Haematol. 2013;162(1):112-119.
244. Celik M, Bulbul A, Aydogan G, et al. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura. J Thromb Thrombolysis. 2013;35(2):228-233.
245. Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer. 2017;64(7):e26389.
246. Kubota M, Adachi S, Usami I, et al. Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study. Int J Hematol. 2010;91(2):252-257.
247. Klassen RJ, Doyle JJ, Krahn MD, Blanchette VS, Naglie G. Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis. J Pediatr Hematol Oncol. 2001;23(8):511-518.
248. Russo G, Miraglia V, Branciforte F, et al; AIEOP-ITP Study Group. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer. 2011;56(2):273-278.

249. Treepongkaruna S, Sirachainan N, Kanjanapongkul S, et al. Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: a multi-center randomized controlled trial. Pediatr Blood Cancer. 2009;53(1):72-77.

250. Grainger JD, Rees J, Reeves M, Bolton-Maggs PH. Changing trends in the UK management of childhood ITP. Arch Dis Child. 2012;97(1):8-11.

251. Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer. 2018;65(1):e26736.

252. Elalfy M, Elbarbary N, Khaddah N, et al. Intracranial hemorrhage in acute and chronic childhood immune thrombocytopenic purpura over a ten-year period: an Egyptian multicenter study. Acta Haematol. 2010;123(1):59-63.

253. Kime C, Klima J, Rose MJ, O’Brien SH. Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children’s hospitals. Pediatr. 2013;131(5):880-885.

254. Neunert CE, Buchanan GR, Imbach P, et al; Intercontinental Cooperative ITP Study Group Registry II Participants. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457-4462.

255. Kühne T, Berchtold W, Michaels LA, et al; Intercontinental Cooperative ITP Study Group. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96(12):1831-1837.

256. Heitink-Polli K, Uiterwaal CSPM, Porcelijn L, et al; TIKI Investigators. Intravenous immunoglobulin versus observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood. 2018;132(9):883-891.

257. Su Y, Xu H, Xu Y, et al. A retrospective analysis of therapeutic responses to two distinct corticosteroids in 259 children with acute primary idiopathic thrombocytopenic purpura. Hematologia. 2009;14(5):286-289.

258. Kane I, Ragucci D, Shatat IF, Bussel J, Kalpatthi R. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura. Br J Haematol. 2010;149(1):79-83.

259. Papagianni A, Economou M, Tragiannis A, et al. Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. J Pediatr Hematol Oncol. 2011;33(4):265-269.

260. Elalfy M, Reda M, Elghannay I, et al. A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia. Transfusion. 2017;57(12):3019-3025.

261. Alioglu B, Ercan S, Tapci AE, Zengin T, Yazari E, Dallar A. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience. Blood Coagul Fibrinolysis. 2013;24(5):505-509.

262. Kjaergaard M, Edslev PW, Hasle H. Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2009;53(7):1315-1317.

263. Payen JF, Berthet M, Genty C, et al; Novoseven Trauma investigators. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding. Br J Anaesth. 2016;117(4):470-476.

264. Shim YJ, Kim UH, Suh JK, Lee KS. Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience. Blood Res. 2014;49(3):187-191.

265. Neunert C, Despotovic J, Haley K, et al; Pediatric ITP Consortium of North America (ICON). Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016;63(8):1407-1413.

266. Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315-e325.

267. Grainger JD, Locatelli F, Chotsampaanchareon T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2016;388(10039):1649-1658.

268. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45-54.

269. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28-36.

270. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol. 2011;90(11):1341-1344.

271. Bussel JB, Hsieh L, Buchanan GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015;62(2):208-213.

272. Grace RF, Bennett CM, Ritchey AK, et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012;58(2):221-225.

273. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144(4):552-558.
Mueller BU, Bennett CM, Feldman HA, et al; Glaser Pediatric Research Network. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52(2):259-262.

Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;265(5):484-491.

Oved JH, Lee CSY, Bussel JB. Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. J Pediatr. 2017;191:225-231.

Miano M, Ramenghi U, Russo G, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology/Oncology. Br J Haematol. 2016;175(3):490-496.

Suvajdzic N, Zivkovic R, Djunic I, et al. Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia. Platelets. 2014;25(6):467-469.

Cooper N, Ghanima W, Provan D, et al. The burden of disease and impact of immune thrombocytopenia (ITP) on patient quality of life and productivity: results from the ITP world impact survey (I-WISH). EHA Library.2018;215096;PF654.

Kruse C, Kruse A, Watson S, et al. Patients with immune thrombocytopenia (ITP) frequently experience severe fatigue but is it under-recognized by physicians: results from the ITP World Impact Survey (I-WISH). Blood. 2018;132(suppl 1):2273.

International ITP Alliance. Global ITP support ambassadors. Available at: http://globalitp.org/index.php/patient-support. Accessed 15 October 2019.

Trotter P, Hill QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 2018;9:369-384.

Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14(1):90-96.

Efficace F, Mandelli F, Fazi P, et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol. 2016;91(10):995-1001.

Kheif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol. 2019;94(2):200-208.

Mathias SD, Gao SK, Rutstein M, Snyder CF, Wu AW, Cella D. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin. 2009;25(2):375-383.

Guidy JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83(3):175-182.

George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409-415.

Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools. J Pediatr. 2007;150(5):510-515, 515.e1.

Klaassen RJ, Mathias SD, Buchanan G, et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012;58(3):395-398.

Heitink-Polle KM, Haverman L, Annink KV, Schep SJ, de Haas M, Bruin MC. Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica. 2014;99(9):1525-1531.

Grainger JD, Young NL, Blanchette VS, Klaassen RJ. Quality of life in immune thrombocytopenia following treatment. Arch Dis Child. 2013;98(11):895-897.

Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer. 2016;69(7):1232-1237.

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol. 2019;185(1):102-106.

Kumar M, Lambert MP, Breakey V, et al; ITP Consortium of North America. Sports participation in children and adolescents with immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015;62(12):2223-2225.

Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr. 2017;6(3):174-180.